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ABSTRACT 
INTRODUCTION: Different genetic features may result in different incidences of diseases, 
treatment response and adverse events following medical therapy. The studies included in this 
thesis collectively aim to identify polymorphisms associated with ankylosing spondylitis (AS) and 
those can predict therapeutic efficacy and adverse events of anti-tumor necrosis factor-α (TNFα) 
treatment in Chinese Han patients. 
METHODS: We performed a case-control study including 149 Chinese Han ankylosing 
spondylitis patients ethnicity- and gender-matched to 106 healthy controls, and genotyped 14genes 
encompassing 28 short nucleotide polymorphisms (SNPs) by using the Matrix-assisted Laser 
Desorption/ionization-time of Flight Mass Spectrometry technique in order to evaluate which 
genes and SNPs are associated with AS. Furthermore, we performed genotyping on 106 Chinese 
Han patients with AS, who received infliximab or a recombinant human TNFα receptor II–IgG Fc 
fusion protein (rhTNFR–Fc) therapy, for evaluating associations between drug response and 
polymorphisms of TNFα gene -238, -308, -857, and -1031. We also conducted a meta-analysis on 
the same set of SNPs in 211 spondyloarthritis (SpA) patients and 392 inflammatory bowel disease 
(IBD) to validate their capability in predicting response toward anti-TNFα therapy. Finally, 402 
Chinese AS patients with anti-TNFα monotherapy were monitored for short-term adverse events 
within two hours. Additionally, long-term adverse effects of anti-TNF therapy were profiled for 
172 patients at 8, 12, 52, and 104 weeks, and their incidences were analyzed for the frequency of 
the aforementioned SNPs of TNFα gene. 
RESULTS: We demonstrated that SNPs in TNFα-857 (rs1799724, p=0.0002), TNFα-308 
(rs1800629, p=0.0484), tumor necrosis factor receptor super-family 1A (TNFRSF1A) (rs4149577, 
p=0.0087), human leukocyte antigen B27tagged (HLA-B27tagged) (rs4349859, p=0.0004), and 
interleukin 23 receptor (IL-23R) (rs1004819, p=0.0131), have close associations with AS. 
Regarding the pharmacogenomics of infliximab and rhTNFR–Fc therapy, we revealed that TNFα 
-857 C/C and -1031 T/T genotypes were significant predictors of treatment response. The results 
from meta-analysis showed that TNFα genotypes -308 G/G (p = 0.0020) and -857 C/C (p = 0.0100) 
responded better to anti-TNFα therapy. By analyzing the side effects of TNF inhibitors (TNFi), 
we found elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as well as 
the duration of disease are highly associated with increased risk for short-term and long-term 
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adverse events (p < 0.05). Additionally, rhTNFR-Fc therapy was associated with less adverse 
events than Infliximab during long-term treatment (p < 0.01). However, when we correlated the 
SNP frequencies in TNFα genes to the occurrence of adverse events, none of them was found to 
be an effective predictor of side effects in AS patients treated with TNF blockers.  
CONCLUSION: Collectively, these studies outline AS-related SNPs in Chinese Han patients. In 
particular, SNPs at promoter regions of TNFαare closely associated with the predisposition of SpA 
and IBD, and responsiveness to anti-TNFα therapy. The prevalence of short- and long-term 
adverse events of TNFi monotherapy were profiled and were not associated with SNPs at TNFα 
promoter. Future studies are expected to confirm these findings in larger cohorts and perhaps 
establish these SNPs as reliable biomarkers at clinics. 
Key words: Ankylosing spondylitis, TNFα, single nucleotide polymorphism, adverse events, 
prediction 
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1.INTRODUCTION 
Working as a rheumatologist in China, I have many patients with ankylosing spondylitis 
(AS)visiting the clinic every day. At present, the first-line therapy for AS is the nonsteroidal anti-
inflammatory drugs (NSAIDs).However, some patients are still in need of tumor necrosis factor 
(TNF) antagonists (Taurog, Chhabra, & Colbert, 2016), a novel biological agent which has been 
proved effective in inflammatory arthropathy. However, not all patients respond to TNF 
antagonists (Maneiro, Souto, Salgado, Mera, & Gomez-Reino, 2015), not to mention that the 
cost of long-term use of this drug is not affordable to most of the Chinese patients. Additionally, 
TNF inhibitor (TNFi) can result in a variety of adverse events; the side effects of this approach 
are not yet very clear among Chinese patients in the real world. Therefore, biomarkers that can 
predict the outcomes, including both efficacy and safety, in patients are urgently demanded. 
Recently, pharmacogenomics combining approaches of pharmacology and genomic analysis has 
been widely applied to predict individual response toward specific medication. Several single 
nucleotide polymorphisms (SNPs) in association with clinical outcomes of TNFi therapy in 
patients with AS have been identified through Pharmacogenomics studies. Our study herein 
performed the first systemic investigation on these SNPs in Chinese AS patients, focusing on 
their association with AS susceptibility, and with the efficacy and adverse outcomes of TNFi 
therapy.  
1.1 The clinical features of SpA and the role of TNFα in AS 
1.1.1 Specific features of SpA 
Spondyloarthritis (SpA) refers to a spectrum of inflammatory diseases including AS, Reactive 
arthritis (RA), Psoriatic arthritis (PsA), Inflammatory bowel diseases (IBD)-related arthritis, 
Juvenile SpA, and undifferentiated SpA. AS is one of the most prevalent chronic inflammatory 
rheumatic disease, affecting the axial skeleton which may additionally involve peripheral joints 
and non-articular structures, causing chronic progressive back pain, spinal motion restriction and 
disability (Corona-Sanchez et al., 2012). IBD is also defined as an autoimmune disease, which is 
characterized by chronic inflammation of the gastrointestinal tract. The manifestation includes 
vomiting, abdominal pain, rectal bleeding, and diarrhea. Gastrointestinal inflammation usually 
occurs in 60% of SpA patients. Among these patients, nearly 10% will develop IBD eventually 
(Rizzo, Ferrante, Guggino, & Ciccia, 2017). More importantly, AS patients exhibited a similar 
profile of immunological changes to IBD patients. For instance, E-cadherin, a cell surface 
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protein dominating the cell type between mesenchymal and epithelial, is enriched in the 
gastrointestinal tissues in AS and IBD patients. This holds true to some other gene/protein, 
including TNFα, a dominant cytokine, and Toll-like receptors-2 and -4 (Tong et al., 2013). 
1.1.2 TNFα as a therapeutic target of SpA 
TNFα is the cytokine mainly produced by monocytes, macrophages and other cell types, such as 
T cells and B cells, natural killer cells, which can generate TNFα in a smaller amount 
(Grivennikov et al., 2005). TNF is a 26kD transmembrane protein (tmTNF), with its extracellular 
domain being cleaved by TNFα-converting enzyme (TACE) to generate soluble TNF (sTNF) 
(Kalliolias & Ivashkiv, 2016). Two receptors interact with both tmTNF and sTNF, among which 
TNF receptor I can activate cell death and NF-κB signaling, which is an anti-apoptotic response. 
In contrast, TNF receptor II stimulates pro-survival and pro-inflammatory pathways (Kalliolias 
& Ivashkiv, 2016). 
TNFα was considered as “a fire alarm of the body”, in that it initiates defense process against 
injury(Feldmann & Steinman, 2005). It conveys benefits to the body against infections when 
present at low concentrations by facilitating host defense system. However, when the 
concentration of TNFα becomes very high, it can result in over activation of the inflammatory 
response and tissue injury. It coordinates with other proinflammatory cytokines, such as IL-1 and 
IL-17, to mediate a spectrum of pathogenic processes, leading to inflammation and tissue 
destruction(Feldmann & Steinman, 2005). TNFα is hence considered at the top of a 
proinflammatory signaling cascade.  
The increased presence of TNFα at an inflammatory site could aggravate disease pathology, 
therefore approaches to eliminate or reduce the amount of TNFα accumulating became a 
therapeutic strategy(Brennan, Chantry, Jackson, Maini, & Feldmann, 1989). Animal studies 
demonstrated that elevated level of TNFα could lead to arthritis spontaneously, a phenomenon 
could be effectively attenuated by inhibition of TNFα (Keffer et al., 1991; Thorbecke et al., 
1992). Hallmarks of chronic inflammation were decreased after receiving TNFα blocker, 
including activation and proliferation of leukocytes, and production of other inflammatory 
factors. Inspired by these pre-clinical results, people performed a pilot study in patients with RA, 
who were given a monoclonal anti-TNFα antibody, known as infliximab today. This study and a 
subsequent multicenter clinical trial both proved that inhibiting TNFα resulted in significant 
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attenuation of disease activity, signs and symptoms of RA (Elliott et al., 1994; Elliott et al., 
1993). As a pro-inflammatory cytokine, TNFα also plays an essential role in SpA and IBD and 
has changed the treatment regimen profoundly. This will be discussed in section 1.3.2. 
1.2 The genetic variants that affect AS 
Ankylosing spondylitis has a strong genetic component to its pathophysiology. For example, in 
Caucasians, 63% of monozygotic twins are both affected, compared to only 12.5% in dizygotic 
twins (M. A. Brown, Kennedy, et al., 1997). 8.2% of first-degree relatives suffer from 
ankylosing spondylitis, whereas second and third-degree relatives are affected by 1% and 0.7% 
respectively. While ankylosing spondylitis disproportionally affects men, disease prevalence and 
severity differs between ethnicities (Braun & Sieper, 2007). For example, 0.1 to 1% of 
Caucasians suffer from ankylosing spondylitis (Van der Linden, Valkenburg, de Jongh, & Cats, 
1984), while the prevalence in China is 0.2 to 0.5% (Ng et al., 2007). However, even in at-risk 
populations the incidence of AS is seemingly lower in Chinese Han patients, with first-degree 
relatives being diagnosed in 3.8% and second and third-degree in 0.9% and 0.3% respectively, 
suggesting protective environmental or genetic factors. Understanding ethnicity-specific 
underlying predisposing and protective genetic factors may therefore be used to identify at-risk 
people. 
SNPs are the most basic genetic variation in the genome (Hinds et al., 2005), and specific 
polymorphisms are indeed associated with ankylosing spondylitis or predict disease severity (M. 
A. Brown, 2008; Seo et al., 2005). Furthermore, conjoined carriage of risk-associated 
polymorphisms compound into higher disease prevalence. Subtle differences in signal processing 
in inflammatory pathways between different ethnicities may lead to marked differences in 
outcomes (Hebert et al., 2012) and complications (Eudy, Vines, Dooley, Cooper, & Parks, 2014). 
Moreover, these differences are highly attributed to the genetic characters in a different population. 
However, coming up with a set of SNPs that accurately predicts the future onset of disease has 
proven difficult. This may in part be due to variation in polymorphism prevalence across 
populations (Gofton, Robinson, & Trueman, 1966) or environmental factors playing a role in 
disease development (Gu et al., 2009). 
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1.2.1 AS-related SNPs in TNFα gene 
SNPs in TNFα have been previously reported in many disease settings, including infectious 
diseases, cancer, and others (Table 1). The advent of genetic screening for polymorphisms has 
also opened the door for pharmacogenomics, a novel branch of medicine that provides therapy 
personalization based on genetic factors. AS is a poorly controlled chronic progressive 
inflammatory process, which will continuously inch a patient closer to the development of 
bamboo spine. Thus, providing patients with the best personalized recommendations on the 
treatment of their disease is perhaps nowhere a paramount task. Several polymorphisms 
susceptible to AS, notably a G to A substitution at position -308(rs1800629) and a C to T 
substitution at position -857 (rs1799724), in the TNFα gene are known to increase the risk for 
ankylosing spondylitis, and correlate with response to anti-TNFα treatment (Chung et al., 2011; 
Sousa et al., 2009). 
1.2.2 Status of HLA-B27 affect AS 
Multiple regions and genes have been implicated throughout various studies and populations. The 
major histocompatibility complex (MHC) region, located on chromosome 6, encompasses 3.6 
megabases including 224 known genes HLA-B27 is an allele of one such gene, and consists of 
over 105 different subtypes(Khan, 2013). Differences in HLA-B27 prevalence drive most of the 
variation in prevalence seen worldwide(M. A. Brown, 2009; M. A. Brown, Kennedy, et al., 
1997).HLA-B27 is generally present in >90% of AS patients, but in <10% of the general 
population (3.6 – 5.7% in Chinese Han) (Zeng et al., 2008), making HLA-B27 almost synonymous 
with autoimmune disease(Brewerton et al., 1973; Khan, 1996). However, of the HLA-B27-
positive individuals in the general population, only 5% develop AS, underlining oligogenic 
pathophysiology(M. A. Brown, 2009). To be sure, HLA-B27 may explain only16% of the overall 
genetic susceptibility of AS, and the entire HLA region only 40-50%(Braun & Sieper, 2007; Lee, 
Rho, Choi, Ji, & Song, 2005).  
Specifically for  Chinese Han patients with AS, HLA-B27 positive patients were 3x more likely 
to have had acute anterior uveitis (p=0.04), higher C-reactive protein levels (p=0.04) but again 
no differences in BASDAI or BASFI (Qian et al., 2017). HLA-B27-positive patients usually have 
an earlier disease onset, and are observed more frequently in male patients in our and previous 
study of Chinese patients, but are not different between genders in other research, suggesting 
potential racial and/or geographical predilection of the Chinese population(Yang et al., 2013). 
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1.2.3 Variants of non-HMC genes that affect AS 
Several genome-wide association studies (GWAS) have reported SNPs related to AS by 
genotyping of large cohorts and have identified a number of non-major histocompatibility 
complex (non-MHC) immune-related risk loci for AS (Australo-Anglo-American 
Spondyloarthritis et al., 2010). Interleukin (IL)-23R, -12β, -6R, -27 and Tyk2 are components of 
IL-23-related pathway.IL-23 was known to drive the differentiation of CD4-positive Th17 cells, 
activation of which generates IL-17. IL-17 can further activate expression and secretion of IL-6, 
-8, TNF and matrix metalloproteinases(Smith & Colbert, 2014). In SpA, differentiation of 
Th17/Th1 cells is mediated by the genetic variants at loci in the IL-23 pathway(Coffre et al., 
2013).The variant in IL-23R is also related to radiographic sacroiliitis in AS in French 
population(Kadi et al., 2013). Two aminopeptidases, including endoplasmic reticulum 
aminopeptidase 1/2 (ERAP1) and (ERAP2) are found to be associated with AS (Robinson & 
Brown, 2014). ERAP1 contains variants associated with either protect against or susceptible to 
AS, and these associations are restricted to HLA-B27-positive AS patients (International 
Genetics of Ankylosing Spondylitis et al., 2013). On the contrary, variants of ERAP2 are more 
linked with AS in HLA-B27-negative patients (International Genetics of Ankylosing Spondylitis 
et al., 2013). ERAP1 variants can alter the antigen presentation and stability of HLA-B27, 
trimming and composition of HLA-B27 ligands (L. Chen et al., 2014). ERAP1, together with 
HLA-B27, are the most powerful predictors of AS. Haplotype of ERAP1 ERAP2 is related to 
familial AS, in that the rs2549782 changes specificity and activity of ERAP2, while rs27044 and 
rs30187 mediate peptide-trimming capacity of ERAP1(Tsui et al., 2010). Other non-MHC loci 
contributable to AS risk include variations in T-cell lineages (EOMES, RUNX3, ZM1Z1, 
BACH2 etc.) and those in G-protein-coupled receptors (GPR35, GPR37, GPR65) (Tsui, Tsui, 
Akram, Haroon, & Inman, 2014). These non-MHC loci were estimated to account for 4.3% of 
heritable AS. 
1.3 Current management of AS 
1.3.1 Conventional therapy of AS 
Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) such as diclofenac, ibuprofen, naproxen, 
celecoxib and etoricoxib are recommended as the first line treatment in patients with ankylosing 
spondylitis which is characterized by alleviating the pain and inflammation response(Vonkeman 
& van de Laar, 2010). NSAIDs reduce back pain and stiffness in AS patients rapidly which 
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through inhibiting the production of prostaglandins by blocking the COX enzyme(Sieper & 
Poddubnyy, 2016). However, NSAIDs have several adverse events in association with morbidity 
and mortality. It may cause gastrointestinal ulcer bleeding, perforation, and obstruction. 
Cardiovascular events have close associations with COX-2-selective NSAIDs and the 
development of hypertension, renal failure, and heart failure need to be considered when short-
term and long-term NSAIDs treatment initiate(Vonkeman & van de Laar, 2010). It is therefore 
unsurprising that the recent availability of anti-TNFα blockers has been widely applied in AS 
patients, as we are now able to directly target a key driver of pathological inflammation (Braun 
et al., 2011; Callhoff, Sieper, Weiss, Zink, & Listing, 2015).  
1.3.2 TNF inhibitors as medical therapy to treat AS patients 
TNF blockers bind to cognate ligands and block their binding to the two TNF receptors. They 
can act as antagonists by blocking tmTNF interactions with TNF receptors, or as an agonist by 
initiating reverse signaling, which induces apoptosis, cell activation or cytokine inhibition 
(Tracey, Klareskog, Sasso, Salfeld, & Tak, 2008). In particular, TNF blockers have been shown 
to be able to reduce manifestations in effectively. TNF inhibitors, including Etanercept, 
Infliximab, Adalimumab, Golimumab, and Certolizumab have delivered on that promise; they 
have shown to attenuate disease progression and improve both function and quality of life 
(Schett, Coates, Ash, Finzel, & Conaghan, 2011).Etanercept is a TNF-receptor Fc-fusion protein, 
binding to both TNF and lymphotoxin family proteins (Tracey et al., 2008). It is a fusion protein 
transcribed by a recombinant DNA fragment. It fuses the soluble TNF receptor 2, which binds to 
TNFα, to the constant end of the IgG1 antibody (Peppel, Crawford, & Beutler, 1991). Etanercept 
shares similar efficacy in treating RA with Infliximab and adalimumab but has less power on 
IBD. Infliximab, adalimumab and golimumab are all full-length bivalent IgG monoclonal 
antibodies, while certolizumab is a monovalent Fab antibody modified by polyethylene glycol 
(Tracey et al., 2008).Infliximab and adalimumab are monoclonal antibodies, binding specifically 
to TNF(Tracey et al., 2008).They share highly similar efficacy in treating RA, PsA, AS and 
Crohn’s disease (Tracey et al., 2008).Infliximab consists of 75% human constant (human IgG1) 
and 25% murine variable domain (binding site of TNFα). The human tract was designed to 
decrease immunogenicity while preserving the functional immune capacity(Sandborn & 
Hanauer, 1999). This calls for pharmacogenomic testing regarding anti-TNFα therapy and drug 
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metabolism when Infliximab is administered to patients. rhTNFR-Fc is a soluble variant of 
etanercept and works as a TNFα-decoy (Tong et al., 2012).  
However, an unresolved issue remains regarding the variety and uncertainty of individual 
response toward this type of medicine. This hurdle is required to be overcome as one has to 
decide whether or not to proceed with the expensive treatment. As such, it is imperative to 
develop an efficient and reliable method to predict the needs and outcome of this therapy. 
Previous reports have identified several SNPs with the predictive capacity of susceptibility and 
severity of SpA and potential response toward TNF blockers. Differences in outcomes and 
adverse events may be magnified by the characteristics lying between individual anti-TNFα 
treatment(Radstake et al., 2009). 
1.3.2 Pharmacogenomic analysis on the association between SNPs and TNFi therapy 
Given the TNF-α plays a central role in the pathogenesis of inflammatory arthritis, TNF 
inhibitors are effective and widely applied for treatment of Rheumatoid arthritis (RA) and SpA. 
However, not all patients benefit from anti-TNF-α therapy, and its side effects are still unclear. 
Currently, patients with inflammatory arthritis have no reliable predictors for TNFi response and 
-associated toxicity. As advances in pharmacogenomics developing, identification of biomarkers 
that can predict TNFi response and adverse events contributing to the development of the better 
clinical decision. Pharmacogenomics is a new study focusing on how genes influence individual 
response to drugs and related toxicity. The distinctive genetic features may predict the outcome 
of medications, which provide a helpful way to increase the efficacy and avoid the severe side 
effects. The pharmacogenomics of TNFi is advancing in the last decade. Single nucleotide 
polymorphisms (SNPs) is the variant of the gene that can be employed to predict drug responses 
as well as toxicity. A variety of SNPs especially in TNF-α promoter have been identified to be 
susceptible for RA and SpA and associated with the response to TNFi. The SNP at position -
308,-238 and -857 of the TNF-α gene have been demonstrated to be associated with 
responsiveness of TNFi in the previous study(Song et al., 2015). However, the results of these 
studies are often varied due to different racial and ethnic populations. Guis et al. reported that the 
RA patients carrying the genotype of TNF-α-308 G/G showed a better response to TNFi than 
those with the genotype of TNF-α-308 A/G (Guis et al., 2007). Seitz et al. have investigated 
polymorphism at locus -308 of TNFα gene influence upon the response to TNFi in patients with 
RA and SpA (PsA and AS) (Seitz, Wirthmuller, Moller, & Villiger, 2007). The study revealed 
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that patients with the genotype of TNFα-308 G/G have better responsiveness to TNFi than those 
with either A/A or A/G genotypes. Padyukov et al. demonstrated that RA patients with TNF-α-
308 G/G and IL-10-1087G/G increase the response to anti-TNFα therapy (Padyukov et al., 
2003). Maxweel et al. have demonstrated that RA patients with a genotype of TNFα-308A/A 
were associated with the poorer response comparing to those with TNFα-308G/G in a soluble 
receptor (etanercept), but not a chimeric monoclonal antibody(infliximab) treated patients 
(Maxwell et al., 2008). In contrast, they found that genotype of TNFα-238 G/A was associated 
with the poorer responsiveness to infliximab rather than etanercept. 
Anti- TNFα therapy has been proved to be useful in the management of inflammatory arthritis. 
However, 30% of patients do not respond to TNFi (Maxwell et al., 2008). Several SNPs seems to 
influence the response to TNFi. However, a large-scale study is demanded to unveil the 
associations with SNPs and the responsiveness of biologics. Due to different ethnicity may 
respond differently to TNFi, the investigations of pharmacogenomics in our Chinese Han 
patients with TNFi are required.   
1.3.3 Current adverse events of anti-TNFα therapy 
Long-term use of TNFi in AS remain necessary for patients to sustain remission. However, the 
safety of prolonged use of TNFi has not been assessed thoroughly in AS(Jani, Dixon, & Chinoy, 
2018). The first generation of TNFi is a fully murine immunoglobulin, which induced intensive 
human anti-murine antibody responses but reduced efficacy. From there, scientist started to 
engineer chimeric proteins, containing murine variable but human constant regions, such as 
Infliximab. Further reduction of the murine component resulted in even less immunogenic 
inhibitors, such as Certolizumab pegol. Later, people can manage to produce fully humanized 
antibodies, such as Adalimumab and Golimumab. Although more humanized antibodies are 
expected to trigger the less immune response, Adalimumab and Golimumab are still doing so. 
Besides, the complicated manufacturing process may introduce subtle differences beyond the 
detection limit, and thus alterations in the biological function and immunogenicity of the produce 
(Dorner et al., 2013). 
The major adverse event of TNFi is infections. TNF recruits leukocytes to infected tissues, 
resulting in activation of macrophage and dendritic cells and hence induces innate immunity or 
regulating acute-phase response(Waters, Pober, & Bradley, 2013).TNFi leads to growing risks of 
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infections (including serious infections) in patients with RA (Michaud, Rho, Shamliyan, Kuntz, 
& Choi, 2014). Regarding AS, there have not been any large longitudinal studies to investigate 
the side effects of TNFi. One clinical trial reported no difference lying between patients on TNFi 
and those not treated with TNFi (Wallis, Thavaneswaran, Haroon, Ayearst, & Inman, 2015). 
However, this result may be due to a lack of statistical power. Tuberculosis (TB) is one of the 
infectious diseases to which AS patients on TNFi therapy are susceptible. This is because TNF, 
by interacting with interferon (IFN)-γ, plays a vital role in the host defense system against 
TB(Mootoo, Stylianou, Arias, & Reljic, 2009). RA patients on TNF blockers exhibited an 
elevated risk of TB compared to those on classical Disease-modifying antirheumatic drug 
(DMARDs)(Ai et al., 2015). The incidence of TB also differs from the kind of TNF blockers in 
use. For example, a much higher chance of TB is found in patients on monoclonal antibodies 
Infliximab and Adalimumab than those on Etanercept(Ai et al., 2015). Unfortunately, fewer 
publications are available regarding AS on this term. Surveys in the country with an increased 
burden of TB did show an increased prevalence of TB in AS patients treated with TNFi (Gomes 
et al., 2015). In addition, six randomized controlled trials, involving 3,886 patients with RA, 
reported opportunistic infections(Minozzi et al., 2016). As TNF is essential to the clearance of 
HBV-infected hepatocytes and HBV virus, TNF blockers may in turn enhance the chance of 
reaction in resolved HBV/occult HBV infection, or ameliorate the active disease (Valaydon et 
al., 2016). 
Other medical concerns following TNFi administration are summarized as follows. Because TNF 
regulates cell growth and death, tumor malignancies are another major concern in patients on 
long-term use of TNF blockers. Several publications reported an increased risk of malignancy 
induced by TNF inhibitors in patients with RA (Bongartz et al., 2006), but none in those with AS 
(Hellgren et al., 2014).TNFi induces cell apoptosis, which inevitably leads to autoantigens 
release and less efficient clearance of nuclear debris, resulting in the formation of autoantibodies 
(Gonnet-Gracia et al., 2008). Induction of antinuclear antibody was found in 52% ~ 87% AS 
patients treated with Infliximab, comparing to 3.3% ~ 27.1% in those at baseline, whereas anti-
dsDNA antibodies were found in 2% ~ 40% (Wronski & Fiedor, 2019).Thus, autoimmune 
diseases, such as lupus-like syndrome and systemic lupus erythematosus, become a class of 
adverse events of TNFi (Perez-De-Lis et al., 2017). Discontinuing TNFi medical therapy can 
effectively reverse the disease (Jani et al., 2017). Infliximab was also shown to increase the risk 
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of heart failure in elderly RA patients (Setoguchi et al., 2008). Paradoxical adverse events, such 
as uveitis, psoriasis, or IBD, have been reported in AS patients on TNF blockers. Usually, these 
extra-articular events were treatment targets of TNFi in SpA. However, their situation could 
become worse by this group of inhibitors (Van der Heijde et al., 2017). One cohort study 
suggested that etanercept may increase the occurrence of uveitis flares in AS patients (Lie et al., 
2017). Etanercept has also been related to the incidence of sarcoidosis when treating RA 
patients(Perez-De-Lis et al., 2017).On the other hand, more than two hundred cases of TNFi-
triggered psoriasis occurred in Crohn disease, RA, and AS(G. Brown et al., 2017), probably due 
to the disequilibrium in cytokine balance(Seneschal et al., 2009). This mechanism also explains 
for the observation that etanercept triggered IBD, a rare paradoxical side effect, in patients with 
AS(Braun et al., 2007).  
1.4 Rationale and design of the study 
1.4.1 Rationale 
The AS disease is characterized by a delay in diagnosis, as initial symptoms are usually 
dismissed as transient ailments by young patients maintaining an active lifestyle  (Tam, Gu, & 
Yu, 2010). However, most of the radiographic progression occurs within the first decade of 
disease onset. Thus, significant disease progression can occur insidiously, with radiographs 
initially revealing irreversible erosive changes at the corners of the vertebral bodies and later the 
development of syndesmophytes. Ultimately, these syndesmophytes fuse with adjacent vertebral 
bodies to form a rigid, calcified spine, called bamboo spine (Tam, Gu, & Yu, 2010).  
Considering the insidious onset of AS and the irreversible damage it causes, screening and early 
detection are of paramount importance to prevent disease progression and pain,as such, 
identifying at-risk patients before the onset of disease would mitigate the delay in both diagnosis 
and start of treatment. This in turn will improve treatment outcomes as currently the best 
predictor for disease progression is disease severity at the time of presentation (Gran & 
Skomsvoll, 1997). 
Previous studies identified a group of genomic features that are associated with the TNFi 
response and adverse events of AS in the Caucasian population. However, several issues 
regarding the pharmacogenomics of TNFi in Chinese AS patients remained to be resolved: 1) 
The validation of previously identified SNP loci has not been conducted in Chinese Han patients 
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with AS. The question is whether they are associated with AS in Chinese population; 2) The 
genetic feature may result in different responses toward TNFi approach. Nevertheless, there has 
not been a comprehensive study to profile the potential response in Chinese Han patients with 
AS. Besides, it is not clear whether polymorphisms of TNFα gene are of predictive value for the 
TNFi treatment response; 3) The adverse events of TNFi monotherapy have not yet been 
reported in a large cohort of Chinese Han patients with AS., And we are not able to predict 
adverse events based on current genetic features. Identifying the predictors of the occurrence of 
adverse events in AS patients treated with TNF blockers could provide potential clues for clinical 
decision. Driven by these unresolved issues, we hypothesized the polymorphisms in the TNFα 
gene have a close association with the efficacy and safety of anti-TNF therapy. Hence, our aim is 
to explore the genetic indicators that can pre-determine TNFi efficacy and the side effects in AS 
patients. To achieve this goal, we conducted the current pharmacogenomic study. 
1.4.2 Study design 
Our first study recruited 149 AS patients and 106 healthy control. We collected peripheral blood 
and isolated genomic DNA, which is subjected to genotyping. Total 28 SNPs in 14 genes that 
were previously reported to be related to ankylosing spondylitis in non-Chinese Han populations 
were analyzed for their associations with AS in Chinese Han patients. In our second study, we 
examined whether polymorphisms in promoter of TNFαat -238, -308, -857, -1031(Figure 1) are 
associated with the outcomes in Chinese Han AS patients (99 patients) when treated with 
infliximab and rhTNFR–Fc, by stratifying patients into good, poor, and no response groups. We 
furtherly performed a meta-analysis to confirm the predictive value of identified SNPs 
indifferent ethnicities and cohorts. Based on the information from our cohort, we also profiled 
the detailed side effects of anti-TNF monotherapy in Chinese Han AS patients and followed-up 
short- (402 patients) and long-term (172 patients) adverse events. Simultaneously, because we 
are curious to investigate whether AS-associated TNFα SNPs are related to the adverse effects, 
each of the SNP was analyzed for its relationship to the occurrence of side effects of anti-TNF 
therapy. The detailed study design and results are described in Section 2-5 as follows. We also 
evaluated whether biomarkers like erythrocyte sedimentation rate and C-reactive protein which 
have demonstrated prognostic value in non-Chinese populations (Ingegnoli, Favalli, & Meroni, 
2011; Lee, Ji, Bae, & Song, 2010; Pavy et al., 2010; Seitz et al., 2007) are predictive in Chinese 
Han patients too. 
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2. IDENTIFY ANKYLOSING SPONDYLITIS-ASSOCIATED SNPs IN CHINESE HAN 
PATIENTS WITH AS (unpublished) 
2.1 Methods 
2.1.1 Patient recruitment for AS-associated SNPs in Chinese Han patients with AS 
The clinical criteria according to 1984 modified New York Criteria for AS includes 1) limitation 
of motion of the lumbar spine in all 3 planes; 2) a history of pain or the presence of pain at the 
(dorso)lumbar junction or in the lumbar spine; 3) limitation of chest expansion (relative to 
normal values corrected for age and sex (Van der Linden, Valkenburg, & Cats, 1984). To 
diagnose AS, one has to meet the following criteria: 1) grade 3-4 bilateral sacroiliitis associated 
with at least 1 clinical criterion; or 2) grade 3-4 unilateral or grade 2 bilateral sacroiliitis 
associated with clinical criterion 1 or with bother clinical criteria 2 and 3 (Van der Linden, 
Valkenburg, & Cats, 1984). One hundred forty-nine Chinese Han patients diagnosed with 
ankylosing spondylitis using the American College of Rheumatology and Modified New York 
criteria, as well as 106 healthy age-, gender- and ethnicity-matched controls were enrolled into 
this study at Chang Hai Hospital, Shanghai. The institutional review board of Changhai Hospital 
(Shanghai, China) approved this study. After written informed consent was obtained, 10 mL of 
blood was collected via venipuncture.  
2.1.2 Genotyping of polymorphisms 
Blood was collected in ethylenediaminetetraacetic acid coated tubes and stored at -80C. 
Samples were digested overnight using 0.5 mg/mL Proteinase K on a 10% SDS gel at 37 C. 
DNA was extracted by using a salting out procedure and isopropanol precipitation. Regions of 
interest were amplified by polymerase chain reaction. Genotyping was performed by matrix-
assisted laser desorption/ionization-time of flight mass spectrometry and MALDI-TOF mass 
spectrometry technique. Table 2 lists investigated SNPs in the ankylosing spondylitis-associated 
SNP experiment.  
2.1.3 Statistical analysis 
Genotypes frequencies were estimated by direct counting and are reported in percent. A χ2test 
was applied to test whether genotypes were in Hardy–Weinberg equilibrium. A p-value equal to 
or smaller than 0.05 was considered significant. The interactions between the protein products of 
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significant SNPs were investigated with STRING (http://string-db.org), with medium level 
confidence (0.400).  
2.2 Results 
Multiple genomic regions and genes have been implicated throughout various studies and 
populations, including European, African, and Asian. Table 3 details the demographics of 
patients and controls. Twenty-eight SNPs in 14 genes that are previously known to be associated 
with non-Chinese Han AS patients (M. A. Brown, Kenna, & Wordsworth, 2016; International 
Genetics of Ankylosing Spondylitis et al., 2013; Reveille, 2012; Sims et al., 2007; Wellcome 
Trust Case Control et al., 2007)were genotyped. Table 4 listed SNPs significantly associated 
with AS, while Table 5 showed those are not. While FOXP3- and IL23R-associated SNPs were 
reported in non-Chinese Han patients, there were no associations found in our cohort for 
rs2232367, rs28935477 andrs11465804. However, in our cohort, HLA-associated SNPs were 
found to be correlated, mainly HLA-B27tagged (rs4349859). 
Table 6 shows an overview of currently known AS-associated SNPs and Figure 2 on how their 
genes and protein products might interact. There are a few common genes contributing to the 
pathogenesis of AS in Chinese Han and Europeans, such as IL-12B, IL-23R, ERAP1, and 
TNFRSF1A, although the variant loci are different between these two populations. Analyzing 
through STRING database, we found that genes containing those AS-associated genetic variants 
indeed have close interactions with each other, suggesting they collaborate to regulate immune 
functions.  
2.3 Discussion 
AS is an autoimmune disease with a strong genetic component and a variable penetration of 
causative genes in various populations. SNPs associated with AS are found in genes that have a 
complex interaction involving antigen mal-presentation, pro-inflammatory cytokines and auto-
destructive T-cells. We demonstrated the association of SNPs in the TNFRSF1A, IL-23R, HLA-
B27 and TNFα genes in Chinese Han patients, in an attempt to further elucidate AS 
pathophysiology, improve diagnostic tools, provide treatment-guiding insights and aid in genetic 
counseling. 
The increased serum TNFαlevels in AS patients are of great clinical significance as they parallel 
pain, fatigue, joint swelling, morning stiffness and disease progression (McLeod et al., 2007; 
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Xueyi et al., 2013). The advent of monoclonal antibody anti-TNFα treatment represents a 
paradigm shift in rheumatology. The TNFα-308 SNP could even be a possible predictor of 
Etanercept treatment efficacy (Chen, 2017; Tong et al., 2012). The SNP rs4149577 in the 
TNFRSF1A gene was associated with AS in both Caucasian and Chinese Han patients (Davidson 
et al., 2011; Karaderi et al., 2012), and was confirmed in this study. SNPs rs1799724 and 
rs1800629 in the TNFαgene were reconfirmed in Chinese Han AS patients (Table 7&8)(Sun, 
Huang, Zhang, & Liu, 2013; Zhu et al., 2007). 
Considering the central role that the TNFα pathway plays in inflammation, it is not surprising 
that several SNPs in the ligand and receptor have been associated with AS (Davidson et al., 
2011). However, as important TNFα may be, the stimulus for TNFα induction remains unknown, 
and the downstream inflammatory pathways are incompletely understood (Feldmann & Maini, 
2008; Tracey et al., 2008). One putative mechanism through which TNFα, IFN-α, and IFN-γ may 
contribute to AS pathophysiology is their capacity to activate the HLA-B27 promoter (Feng, 
Ding, Fan, & Zhu, 2012). Another possible mechanism is through the induction of auto-
destructive CD4+T cells and CD8+T cells (Duftner et al., 2003; Rudwaleit et al., 2001; 
Schirmer et al., 2002). Additionally, white blood cells in the sacroiliac joints of AS patients 
express high levels of TNFα(Braun et al., 1995), but anti-TNFαtreatment does not reduce bone 
erosion allowing syndesmophyte formation to continue. Therefore, the interplay with other 
cytokines needs to be considered (Van der Heijde, Landewe, Baraliakos, et al., 2008; Van der 
Heijde, Landewe, Einstein, et al., 2008; Van der Heijde et al., 2009). 
Here we have confirmed the association with the rs4349859 SNP in the HLA-B27 gene in Chinese 
Han patients, as was previously demonstrated in other populations (Evans et al., 2011). 
Subsequently, non-HLA SNPs have been mapped. These non-HLA SNPs are of pivotal 
importance to disease pathophysiology as is illustrated by Gambian Fula populations, where HLA-
B27 carriage is 6% but AS does not occur (M. A. Brown, Jepson, et al., 1997). 
The IL-23R is a hemopoietin type receptor with affinity for its proinflammatory namesake. The 
SNPs rs11209032, rs11209026 and rs11465817 are associated with AS in Caucasian populations 
(Australo-Anglo-American Spondyloarthritis et al., 2010; Burton et al., 2007; Karaderi et al., 
2009), but not Asian populations (Chen, Zhang, Li, & Wang, 2012; Davidson et al., 2009; Lee, 
Choi, Ji, & Song, 2012; Qian et al., 2013). However, conflicting results have been reported for 
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SNPs rs11209032 and rs6677188 in Chinese Han patients in other reports (Wang et al., 2010). 
We reported that an SNP on rs1004819 is significantly associated with Chinese Han AS patients. 
Overall, the population-attributable risk associated with IL-23R is approximately 1% (Australo-
Anglo-American Spondyloarthritis et al., 2010; Burton et al., 2007). 
Activation of the IL-23 receptor induces Signal transducer and activator of transcription 3 
(STAT3) phosphorylation and thereby the production of IL-17, IL-6, IL-8, and TNFα, thus 
amplifying and stabilizing γδT cells and CD4+Th-17 autoimmune lymphocytes (Kenna et al., 
2012; McGeachy et al., 2009; McKenzie, Kastelein, & Cua, 2006; Trinchieri, Pflanz, & 
Kastelein, 2003). The association of multiple SNPs in the genes involved in the pathogenic Th-
17 cell pathway, including IL-23R, STAT3, and IL-12B (an IL-23 subunit), suggests this is an 
essential pathway in AS. Indeed, serum levels of IL-23 (Xueyi et al., 2013), IL-17 (Mei et al., 
2011), and IL-1B are elevated in AS patients. Furthermore, IL-23 and IL-17 serum levels 
increase upon binding of prostaglandin E2 to the prostaglandin E-4 receptor. SNPs in the 
prostaglandin E-4 receptor gene, PTGER4, have been associated with AS (Evans et al., 2011). 
Non-steroidal anti-inflammatory drugs slow heterotopic ossification and radiographic 
progression in AS (Baird & Kang, 2009; Poddubnyy et al., 2012), thereby underlining the 
importance of cytokines and pro-inflammatory autoimmune T-cells in AS pathophysiology.  
SNPs in the ERAP1 and ERAP2 genes have been robustly associated with HLA-B27-positive AS 
in both Caucasian and Chinese Han patients. ERAP1trims peptides to optimal length in order that 
they can be presented by MHC class I molecules within the endoplasmic reticulum (Saveanu et 
al., 2005). Because of this function, it is presumed that SNPs in these genes lead to aberrant 
processing and presentation of antigenic peptides. The population-attributable risk associated 
with ERAP1 is 26% (Australo-Anglo-American Spondyloarthritis et al., 2010; Burton et al., 
2007). Combined HLA-B27 and ERAP mutations are predictive of increased disease severity 
(Szczypiorska et al., 2011). Additionally, the SNP rs27037 is predictive of syndesmophyte 
formation in AS, suggesting subtype of AS may exhibit unique SNP characters that may be 
omitted when the population was mixed up (Wang et al., 2012).ERAP1 also sheds the TNFα, IL-
1 and IL-6 receptors off of the cell surface (Cui, Rouhani, Hawari, & Levine, 2003b). These 
receptors subsequently become cell-free, act as decoys and by less availability of respective 
receptors on the cell surface increase cytokine activity (Cui, Rouhani, Hawari, & Levine, 2003a; 
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Thomas & Brown, 2010). The clinical importance of mechanism is still under investigation. 
However, our results did not find associations between SNPs of ERAP1 and incidence of AS. 
This controversy might attribute to the limited sample size and insufficient statistical power. 
In particular, the results showed that these genes are associated with defense response 
regulation/immune system process (e.g.CARD9(Ruland, 2008),ERAP1(Alvarez-Navarro & 
Lopez de Castro, 2014), HRAS(Castellano, De Las Rivas, Guerrero, & Santos, 
2007),PTPN22(Bottini & Peterson, 2014),RAF1(Odabaei et al., 2004)) and osteoclast 
differentiation (e.g.TNF(Martin, Romas, & Gillespie, 1998), IL-12B(Martin et al., 1998), 
PPARGC1B(Ishii et al., 2009)), suggesting AS-related SNPs are extensive distributed in 
immunoregulatory and developmental related pathways. Subsequently, non-HLA SNPs have 
been mapped. These non-HLA SNPs are of pivotal importance to disease pathophysiology as is 
illustrated by Gambian Fula populations, where HLA-B27 carriage is 6% but AS does not occur 
(M. A. Brown, Jepson, et al., 1997). 
As illustrated by the gene polymorphism and associated gene-protein networks among 
susceptible genes we found and summarized from previous studies, the protein products of TNFα 
and IL-23R genes play a dominant role in a predictive network. Interestingly, evidence of anti-
TNFα therapy presents a solid treatment for the patients with AS, and also new compounds that 
target the IL-23 receptor may provide a potential opportunity for advances in the treatment of 
ankylosing spondylitis.  
Overall, the etiology of AS is complex and only partly understood. SNP findings provide limited 
clues on the pathogenesis of AS, and the analysis of associated protein products advances the 
development of biologics and small molecules that specify on these predominant cytokines. The 
relevant lines of further investigation are to integrate with the detailed biology of the risk factors, 
especially with respect to how these risk factors may affect the pathogenic process and clinical 
outcome.  
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3. THE STUDY OF TREATMENT RESPONSE-PREDICTIVE SNPs IN CHINESE HAN 
PATIENTS WITH AS 
3.1 Methods 
3.1.1 Patient recruitment 
One hundred six Chinese Han patients identified from the Changhai Hospital Ankylosing 
Spondylitis database who were diagnosed with ankylosing spondylitis using the Modified New 
York criteria (Van der Linden, Valkenburg, & Cats, 1984), as well as 106 healthy ethnicity-
matched controls were enrolled into this study. Seven patients were lost during follow-up. The 
institutional review board of Changhai Hospital (Shanghai, China) approved this study. 
Exclusion criteria for this study were the use of disease-modifying anti-rheumatic drugs in the 
last three months, as well as a diagnosis of any chronic infectious diseases, cancer, hepatic or 
renal dysfunction, hematological and cardiac conditions or multiple sclerosis. After written 
informed consent was obtained, patient demographics and disease pertaining information was 
collected using the Assessment of SpondyloArthritis International Society (ASAS) criteria and 
the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)(Anderson, Baron, van der 
Heijde, Felson, & Dougados, 2001; Garrett et al., 1994). Four components were included in the 
“ASAS 20 improvement criteria”, namely patient global, pain, function (assessed by BASFI), 
and inflammation. When three of these four essences are improved by ≥ 20% and a minimum of 
one unit on a scale of 0 to 10, a patient meets an ASAS 20 response. In the remaining 
component, no worsening of 20% and a minimum of 1 unit, on a 0 to 10 scale, should be 
met(Anderson et al., 2001). Similarly, ASAS 40, 50, and 70 response respectively require the 
improvement to be no less than 40%, 50% and 70%, for three out of four components, and no 
worsening than 40%, 50% and 70% in the remaining one(Brandt et al., 2004). BASDAI covers 
six questions on fatigue, spinal pain, peripheral joints, entheses, intensity of morning stiffness, 
and duration of morning stiffness(Garrett et al., 1994). A numerical rating scales (NRS) or a 10 
cm visual analog scale (VAS) is used for scoring each question. The final BASDAI score is 
derived from the summation of the first four questions and the mean value of the last two 
questions, after dividing by five. The scale of the final score is 0 (no disease activity) to 10 (very 
active disease). To define active disease, the frequently used cutoff is 4.  
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3.1.2 Genotyping of polymorphisms 
Blood was collected in ethylenediaminetetraacetic acid coated tubes and stored at -80C. 
Samples were digested overnight using 0.5 mg/mL Proteinase K on a 10% SDS gel at 37 C. 
DNA was extracted using a salting out procedure and isopropanol precipitation. Regions of 
interest were amplified by polymerase chain reaction. Genotyping was performed by matrix-
assisted laser desorption/ionization-time of flight mass spectrometry and MALDI-TOF mass 
spectrometry technique. Table 9 shows the primer sequences for TNFα genotypes -238 
(rs361525), -308 (rs1800629), -857 (rs1799724) and -1031 (rs1799964) used in the experiment 
investigating TNFα SNPs to treatment outcome.  
3.1.3 Clinical Evaluations 
Patients were evaluated in the end of 12 weeks of treatment by using the ASAS-score. This 
evaluates patients based on global, pain, function and inflammation. Patients were deemed non-
responders if no improvement was shown based on their baseline ASAS-score. Patients were 
deemed good responders if they achieved a global improvement of ≥40, 50and 70%, along with 
a ≥2-point improvement in pain, function and inflammation and a maximum of 1-point 
deterioration in other the final category. All other patients were deemed poor responders. 
Positive cut-off points of biochemical parameters include an erythrocyte sedimentation rate of 20 
mm/h in men and 15 mm/h in women and a C-reactive protein of 8 mg/L. The HLA-B27 titers 
were quantified. Disease activity and functionality were assessed using the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) (Garrett et al., 1994) and Bath Ankylosing 
Spondylitis Functional Index (BASFI) (Calin et al., 1994). 
3.1.4 Statistical analysis 
Clinical comparisons were performed in SPSS v18 using the student’s T-test for continuous 
normal distributed variables, the Wilcoxon’s Rank Sum test for continuous non-normal 
distributed variables and the χ2 test was used for categorical variables. Genotype-response 
association analysis was also performed using the χ2. A p-value of 0.05 or smaller was 
considered significant.  
3.2 Results 
3.2.1 Demographics 
Table 10 details the demographics of the patients in this clinical cohort. The average age was 41 
± 16 years with a male predominance (78%) and an average disease duration of 9.5 ± 9 years. 
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Symptoms started with inflammatory backpain or alternating buttock pain in 55% and peripheral 
involvement (e.g., enthesitis, dactylitis, arthritis and acute anterior uveitis) in 45%. HLA-B27 
carrier status was found in 92%. The average C-reactive protein was 35 ± 19 mg/L. Among all 
subjects, 91.92% wereHLA-B27-positive. The mean value of erythrocyte sedimentation and CRP 
were 36 ± 17 and 35 ± 18mg/dl. On the other hand, patients who were administered with 
infliximab and rhTNFR–Fc took 28% and 71% respectively. Baseline patient characteristics did 
not differ regarding predictive SNPs per type of therapy. 
3.2.2 AS-related TNFα SNPs in patients versus controls 
Table 7 details the demographics of patients and controls regarding the 4 TNFα SNPs 
investigated with this cohort. For each allele, these four SNPs were compared between AS and 
healthy controls. All genotype distributions were in Hardy-Weinberg equilibrium. In elevated 
frequency of G/G phenotype was observed for TNFα -308 polymorphism in AS group (p = 
0.0093). However, TNFα-238 and TNFα-1031 polymorphisms were not significantly different 
from each other. AS patients showed a significantly distinct frequency of TNFα-857 (C/T 
genotype) than the control group (p = 0.00001). Specifically, T allele is the predominant 
genotype in Chinese Han AS population (p = 2.455 × 10-7). Additionally, the patient cohort was 
enriched for the G/G genotype at the -308 position as well as the C/T and the T genotype at the -
857 position. 
3.2.3 Predictive TNFα SNPs in TNFi non-responders versus responders 
Table 8 details a comparison between non-responders and responders (ASAS ≤ 20 versus 
ASAS ≥ 40) for all four SNPs of interest. Different genotypes present a different level of 
response toward anti-TNF treatment. Specifically, at locus TNFα -857 rs1799724, patient with 
genotype C/C (n=1), genotype T/T (n=3), and genotype C/T (n=4) exhibited no response at all. 
Similarly, at locus TNFα -1031 rs1799964, patient with genotype C/C (n=3), genotype T/T 
(n=3), and genotype C/T (n=2) responded at ground level. Moreover, at locus TNFα -308 
rs1800629 (p=0.602) and TNFα -238 rs361525 (p=0.426), G/G genotype (n=8), A/G genotype 
(n=1), and G/G genotype (n=7), respectively, were not responding to the therapy. In summary, 
TNFα SNPs investigated in this cohort did not differentiate between non-responders and 
responders.  
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3.2.4 Predictive TNFα SNPs in good responders versus not-good responders 
Table 11 details a comparison between responders and the remaining patients (ASAS ≥ 40 
versus < 40) for all four SNPs of interest. The response level and quality cannot be predicted 
solidly from the allelic polymorphism at TNFα-308 rs1800629 and TNFα-238 rs361525. At 
TNFα-857 rs1799724, however, a good response can be foreseen (χ2 = 12.285; p-value equals to 
0.0021). In addition, at TNFα-857 rs1799724, a genotype of C/C in Chinese Han AS patients 
exhibited a better response toward TNFαblocker, comparing to those with genotypes of C/T or 
T/T. Besides, a good response (χ2 = 15.645; p-value equals to 0.0004) and treatment outcome 
could also be predicted with the polymorphism at TNFα-1031 rs1799964 locus by bearing a T/T 
genotype rather than a C/T or C/C genotypes. Furthermore, another locus at -875 of TNFα can 
facilitate the prediction of good response (χ2 = 10.488; p-value equals to 0.0012). Lastly, T allele 
at -1031 position exhibited effective response as well in Chinese AS patients (χ2 = 7.473; p-value 
equals to 0.0063). Overall, polymorphisms at -857 with a C/C genotype responded well to 
treatment, while C/T or T/T genotypes did not. Polymorphisms at -1031 with a T/T genotype 
responded well to treatment, while C/T and C/C did not. The C-allele at -857 and the T-allele at -
1031 predicted good treatment response. 
3.3 Discussion 
Remarkable variations occur in response to treatment in Chinese Han AS population. Emerging 
evidence, although not conclusive, suggest that certain biomarkers can predict the response to 
anti-TNFα therapy.  
The TNFα protein is a potent pro-inflammatory cytokine and immune modulator of joint 
destruction, and TNFαis possibly considered as a risk factor for developing SpA (Romero-
Sanchez et al., 2012). TNFαstimulates the expression of adhesion molecules and increases 
neutrophil activation. Polymorphisms at TNFαgene was shown to be the predictor of the 
response toward TNFαblocker treatment in Caucasian AS population (Seitz et al., 2007). A 
number of studies have reported that TNFαgene transcription is regulated by its polymorphisms, 
and in most cases the polymorphisms reduced the gene expression and lead to a more significant 
of TNFα suppression (Kooloos, Wessels, van der Straaten, Huizinga, & Guchelaar, 2009; Lv, 
Chen, Cai, Fang, & Sun, 2006; Marotte, Arnaud, Diasparra, Zrioual, & Miossec, 2008). 
Subsequently, several studies reported contradictory results: Six showed that TNFα-308 A/G 
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polymorphism are associated with TNFαblocker treatment in RA for both Western and Asian 
people(Aguillon et al., 2006; Guis et al., 2007; Maxwell et al., 2008; O'Rielly, Roslin, Beyene, 
Pope, & Rahman, 2009; Plant et al., 2011), whereas three studies found that TNFα-308 G/G 
polymorphism and variants spanning type 2 TNF receptor (TNFR2) and TNF cleavage enzyme 
(TACE) genes are not related to TNFi response(Potter et al., 2010; Soto et al., 2011; Suarez-
Gestal, Perez-Pampin, Calaza, Gomez-Reino, & Gonzalez, 2010). This inconsistency might be a 
consequence drove us to initiate this study in Chinese AS patients.  
The availability of effective anti-TNFαtreatment has been challenged with enormous economic 
and social value. To identify the predictors for TNFα blocker responsiveness is highly valuable, 
due to the high medical cost and the possibility of unknown side effects. Two distinct characters 
lies in our study: 1) we are the first study to identify TNFi response-associated SNPs in Chinese 
Han AS patients; 2) the inhibitors provided to our patients include infliximab and rhTNFR-Fc 
(product name: YiSaiPu), a biosimilar of etanercept produced by Shanghai CP Goujian 
Pharmaceutical Co. in China and a most widely prescribed TNFi due to insurance coverage by 
Chinese government. However, the pharmacogenomics of rhTNFR-Fc has never been 
investigated in AS patients.  
Two polymorphisms, namely TNF -308 G/A and -857 C/T, are the most commonly studied ones 
for assessing response toward anti-TNFα therapy. Our research failed to recapitulate the 
predictive value of -308 SNP but confirmed that -857 C/C genotype could predict good response. 
This is in contrary to a previous study, which showed -308 G/G phenotype exhibiting a better 
response to anti-TNF therapy(Seitz et al., 2007). Such inconsistency might be a result of 
inadequate sample sizes and statistical power. To overcome these issues, we performed a meta-
analysis to increase the population size while reducing the random errors that may yield false-
positive or -negative results. Although a few meta-analyses have examined the relationship 
between effects of TNF blockers and TNF polymorphism in rheumatoid arthritis (Lee et al., 
2010; Pavy et al., 2010; Seitz et al., 2007; Zeng et al., 2013), less is known in SpA. Hence, our 
present research provided the first evidence regarding this issue. 
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4. META-ANALYSIS OF TNFα SNPs PREDICTING ANTI-TNFα TREATMENT 
RESPONSE IN PATIENTS WITH SPA AND IBD 
4.1 Methods 
4.1.1 Meta-analysis of TNFi-associated SNPs in SpA and IBD 
We performed a meta-analysis for original studies reporting associations between single 
nucleotide polymorphisms at both -308 and -857 of the TNFα-gene and outcome of anti-TNFα 
treatment. A search using PubMed and Elsevier’s Science Direct was performed for publications 
as recent as February 2013 using the following entry: “TNF-α OR TNFα OR Tumor necrosis 
factor OR TNF blocker ORTNF therapy OR infliximab OR etanercept OR adalimumab OR 
polymorphism 857 OR polymorphism308 OR spondyloarthritis OR SpA OR ankylosing 
spondylitis OR psoriatic arthritis OR Crohn’s disease OR enteropathic arthritis OR PsA OR 
IBD”. No filters were applied. References to suitable studies within the citations of publications 
matching to our query were included in the meta-analysis. When necessary investigators were 
contacted for missing information or additional data. 
4.1.2 Statistical analysis 
RevMan 5.0 was used in the meta-analysis. Dichotomous data were reported as the odds ratio 
and a 95% confidence interval. A p-value equal to or smaller than 0.05 was considered 
significant. A Z-test determined the significance of the pooled odds ratios. We evaluated within- 
and between-study heterogeneity using the Cochran’s Q-statistic (Zeggini & Ioannidis, 2009) 
with a p-value equal to or smaller than 0.10 indicating heterogeneity across studies. Furthermore, 
we quantified the effect of the heterogeneity using a I2. 25% was considered low, 25% was 
considered moderate and 75% high. A fixed effects model was applied using the Mantel–
Haenszel method for non-heterogeneous results, otherwise a random effects model was applied 
using the Der Simonian and Laird method (Zeggini & Ioannidis, 2009). Publication bias was 
assessed using a funnel plot. 
4.2 Results 
4.2.1 Detailed description for studies included for meta-analysis 
Because AS and IBD share similar immunologic alteration and same epitome, and previous 
studies have found that there are many common susceptible genes to both diseases, we 
investigated these two diseases together in our meta-analysis. Table 12and Figure 3 detail the 6 
studies that met the inclusion criteria for the meta-analysis (Duricova et al., 2009; Louis et al., 
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2002; Seitz et al., 2007; Tong et al., 2012; Vasilopoulos et al., 2012; Vermeire et al., 2000), 
which include a total of 211 spondyloarthropathy patients (SpA) (121 ankylosing spondylitis and 
90 psoriasis / psoriatic arthropathy) and 392 inflammatory bowel disease (IBD) patients. 
Depending on the study, patients were evaluated after 30 days to 6 years. Infliximab 
monotherapy was applied in three studies, whereas the remaining three studies treated with either 
etanercept or adalimumab. Our meta-analyses demonstrated no heterogeneity among studies 
(p>0.1). Therefore the fixed effects model was applied. Publication bias was not detected for 
either polymorphisms meta-analyses. Five independent research groups examined the association 
of -308 A/G polymorphism at TNFα promoter in one hundred thirty-one SpA patients and three 
hundred nighty two IBD patients. Among these reports, merely three of them successfully 
recapitulated the association between -857 C/T genotype and response toward TNFαblockers in 
one hundred seventy-nine SpA patients and one hundred and one IBD patients.  
4.2.2 SNPs of TNFα -308 and -857 predict the TNFi response 
The TNFα-308 A/G polymorphism was investigated by five studies, including 131 
spondyloarthropathy and 392 inflammatory bowel disease patients. The TNFα-857 C/T 
polymorphism was investigated in three studies, including 179 spondyloarthropathy and 101 
inflammatory bowel disease patients.  
Other than A/G variants at TNFα-308 position, we also compare the genotypes between G/G and 
(A/A+A/G), (A/G+G/G) and A/A. The comparison illustrated both the dominant and recessive 
aspects of the model in the G allele. Table 13 lists the results of the -308 polymorphisms meta-
analysis. G allele was associated with better treatment response over the A allele, as did the G/G 
genotype over the G/A or A/A genotypes. Because inadequate data was included, a funnel plot 
was not able to be depicted for assessing publication bias. With a p-value greater than 0.1, the 
studies included seem to have little heterogeneity. Therefore, the fixed model was valid for 
utilization. G allele, according to the OR (2.14) and 95% CI range (1.38-3.33) as well as p-value 
(0.0007), suggested a better response than that of A allele. On the other hand, in patients treated 
with TNFα blocker, G/G genotype seems to receive a better outcome than that of G/A+A/A 
genotype, evidenced by OR equals 2.31, 95% CI ranges from 1.36 to 3.91, and p-value equals 
0.002. There is no difference between A/A genotype and A/G+G/G. See Figures 4-6 for details.  
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In addition to TNFα-308 A/G, our study also compared the allelic effect between several pairs, 
including C and T, C/C and C/ T+T/T, C/C+C/T and T/T. Because inadequate data was included, 
a funnel plot was not able to be depicted for assessing publication bias. With a p-value greater 
than 0.1, again, the studies related to TNFα -857 C/T included seem to have little heterogeneity. 
With an OR equals 2.17, 95% CI ranges from 1.17 to 4.03, and a p-value of 0.01, C allele 
exhibited a significant between response toward TNFα blocker than T allele. Moreover, T allele 
bears a significantly lower OR value (3.66) in the responder group. C/C+C/T is not significantly 
different than T/T genotypes. Table 14 lists results for the -857 polymorphism meta-analysis. 
Here, the C allele was associated with a better treatment response over the T allele, but the C/C, 
C/T and T/T genotypes were not predictive. See Figures 7-9 for details. 
4.3 Discussion 
The present meta-analysis suggests that TNFα gene polymorphisms at the -308 and -857 
positions could predict therapeutic response with TNFα blocker, several clinical aspects remain 
to be clarified. Only six studies met the selection criteria which were included in our research, 
many more studies of different ethnic populations are needed to detect the association between 
TNFα polymorphisms and responsiveness to TNFα blocker. Meanwhile, sophisticated studies 
dissecting the co-function of TNFα-308, -857 and other genes with response to anti-TNFα 
therapy are required in large details. In the future, pharmacogenomics will be widely utilized in 
SpA and IBD with TNFα blocker for personalized medication. The -308 G/G genotype and/or -
857 C/C genotype could guide us to select appropriate patients for anti-TNFα therapy. 
Surprisingly, an independent cohort study performed by us in the Chinese Han population 
showed that genetic polymorphisms at -308 and -238 of TNFα gene are not able to predict 
therapeutic responses toward anti-TNFα therapy. In contrast, either TNFα -587 C/C or -1031 T/T 
alone turned out to be useful predictors of good response. Combining both did improve the 
prediction efficacy. Our study emphasizes the fact that population-specific predictors shall be 
developed to account for precise medical treatment.  
Our meta-analysis revealed that for both TNFα-308 or -857 polymorphisms, the common allele 
(G and C, respectively) showed a better response to the TNFα blocker than the minor allele (A 
and T, respectively). In addition, it also showed a significant difference between the minor allele 
carrier (GA+AA and CT+TT) and non-carrier states (GG and CC). Among the five studies 
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detecting the association of TNFαpromoter -308 A/G polymorphism with responsiveness to 
TNFα blocker, only Seitz et al. demonstrated a positive result as to G allele and GG genotype 
(Seitz et al., 2007), and Vermeire found a significantly positive association between carriers of 
allele G and treatment response (Louis et al., 2002). The other three studies showed no relevant 
association of TNFαpromoter-308 A/G polymorphism and therapeutic response (Duricova et al., 
2009; Louis et al., 2002; Tong et al., 2012). Among the three studies detecting the association of 
TNFα promoter-857 C/T polymorphism with responsiveness to TNFα blocker, Tong showed the 
-857 C/C genotype responded better to therapy (Table 15)(Tong et al., 2012)and Vasilopoulos 
revealed carriage of TNFα-857C was related with positive response to anti-TNFα treatment 
(Vasilopoulos et al., 2012). Our meta-analysis showed entirely different results from the studies 
included. The explanation for this phenomenon may be because we used meta-analysis to 
combine inconsistent results from several studies to explore a result for SpA. However, despite 
belonging to SpA, different diseases such as AS and PsA may have a different mechanism for 
the response to TNFαblocker. 
As the first meta-analysis study concerning TNFα polymorphism and therapeutic response in 
SpA patients, we compared our results with other meta-analyses examining RA patients. In 2010, 
Lee et al. showed that there was no significant difference in the proportions of TNFα promoter -
308A allele carriers in a group that responded to treatment and a group that did not (Lee et al., 
2010), while Pavy et al. came to the same conclusion (Jahan et al., 2017). In2012, Zeng 
concluded that there was no significant difference between GG and (GA+AA)with 
responsiveness to the TNFα blocker (infliximab, etanercept and adalimumab) (Zeng et al., 2013), 
which conflicted with our results. Several reasons could be considered: SpA and RA are different 
diseases and may have different mechanisms for the response to TNFα blocker; Zeng et al. 
included 15 studies with a total of 2127 patients in their meta-analysis, which is of a larger 
sample size than that outlined here. At the same time, subgroup analysis was performed based on 
different response criteria (disease activity score 28 [DAS28] and American College of 
Rheumatology 20% improvement criteria [ACR20]) in his study. Subgroup analysis could 
explore the source of heterogeneity and reduce the possible influence factor, thus providing more 
accurate results. There are still several limitations in our present study. Firstly, owing to the fact 
that only six studies met the criteria and were included in this meta-analysis, we could not rule 
out the existence of publication bias, which may affect the results. More studies are needed to 
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detect the association of TNFα polymorphism and responsiveness to TNFαblocker. Secondly, 
albeit differences exist among different ethnic populations, TNFα antagonists are widely used in 
the world and show excellent efficacy. Our meta-analysis aims to demonstrate the role of TNFα 
genes in predicting responsiveness to different TNFα antagonists. That is why we included a 
variety of TNFα blocker (infliximab, etanercept and adalimumab) rather than only one of them. 
In this meta-analysis, only six studies were included owing to our rigid inclusion and exclusion 
criteria. Among the six included studies, only one Asian cohort was incorporated (Tong et al., 
2012); the other cohorts comprised European SpA and IBD patients. Therefore, more studies on 
Asians should be included in future meta-analyses. 
5. ADVERSE EVENTS AND ASSOCIATED SNPS OF ANTI-TNFα THERAPY 
5.1 Methods 
5.1.1 Patient recruitment 
Total 402 Chinese Han patients presenting at the department of rheumatology at Changhai 
Hospital who was diagnosed with ankylosing spondylitis using the Modified New York criteria 
(Van der Linden, Valkenburg, & Cats, 1984) were enrolled into this study. Signed informed 
consent was obtained from patients who were randomized to rhTNFR-Fc or infliximab 
monotherapy and outcome data regarding short-term and long-term side effects were collected 
during the study period June 2008 to February 2013. The institutional review board of Changhai 
Hospital (Shanghai, China) approved this prospective clinical study. Exclusion criteria listed 
under 2.1.3 were applied. There are a total of 113 patients with non-adverse event, among which 
31 patients do not have SNP information. Meanwhile, 20 patients out of 51, who have adverse 
events, have no SNP information. Hence, 82 patients with the non-adverse event and 39 with 
adverse events were included to analyze the side effects-related polymorphisms of TNFα. 
5.1.2 Loss to follow-up 
Enrollment commenced in 2008 and concluded in 2013, and of the 402 patients in this study, 230 
were lost to follow-up for the study of long-term adverse events (87 receiving infliximab and 85 
receiving rhTNFR-Fc). In 162 out of 230 cases of loss to follow-up, the main reason was the 
financial burden associated with a not (fully) reimbursed treatment. Other causes of loss to 
follow-up were treatment failure (20 cases) or complications (19 cases). These patients 
transitioned into NSAIDs plus DMARDs co-therapy under our care. A further 23 patients were 
lost due to relocation, five dues to unknown reasons, and one due to non-small cell lung cancer. 
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5.1.3 Study design 
Participants received either 200 mg infliximab (n=32) intravenously at week 0, 2 and 6, or 25 mg 
rhTNFR-Fc (n=74) twice weekly for 12 weeks subcutaneously. Upon administration, participants 
were put under observation for 2 hours to monitor for side-effects, which were categorized as 
mild when symptoms spontaneously resolved within the hour, moderate when medical 
intervention was required, and severe when hospitalization was required or in case of a fatality.   
5.1.4 Statistical analysis 
Clinical comparisons were performed in SPSS v17using the student’s T-test or Pearson’s chi-
square test. Results were considered significant when the p-value is lower than 0.05.  
5.2 Results 
5.2.1 Demographics 
Table 16 details patient demographics in this study(Tong et al., 2015). The cohort consisted of 
375 men and 27 women, a total of 402 patients with an average age of 39.5 ± 16 years. 
Therefore, men took up to 93.3 percent of the entire cohort with an average age at 39 ± 15. Two 
hundred ten patients received rhTNFR-Fc monotherapy, and 192 received infliximab 
monotherapy. See Table 16 for a list of side effects occurring in this study. Side effects of 
treatment typically comprise a spectrum of infectious diseases, such as pneumonia (thirteen 
cases), urinary infection (seventeen cases), otitis media, and oral candidiasis. The first two types 
take up to fifty percent of all events. Overall, pneumonia(22.0%) and urinary tract infections 
(28.9%) combined caused the majority of the toxicities. Urinary tract infections occurred at a 
significantly higher frequency in the infliximab-group (p equals to 0.0325). 
 
5.2.2 Short-term side effects 
Table 18 details the prevalence of short-term side effects. Twenty percent of the cohort suffered 
from adverse events within 2 hours since the beginning of treatment, affecting forty-six patients 
treated with rhTNFR-Fc and thirty-five patients that are treated with infliximab. Adverse events 
rate was not different between treatment groups. Patients experiencing early onset toxicities were 
younger, had short disease duration and primarily peripheral involvement of disease but had 
lower C-reactive protein levels and erythrocyte sedimentation rates(p=10-5) paradoxically. 
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5.2.3 Long-term side effects 
Table 19 details the prevalence of long-term side effects. Total one hundred and seventy-two AS 
patients have follow-up data. These include eighty-seven and eighty-five patients receiving two 
hundred milligram Infliximab per 6 weeks and twenty-five milligram rhTNFR-Fc biweekly, 
respectively. The treatment lasted for one hundred and four weeks, that is from 2008 (study 
began) to 2013 (study concluded). Fifty-nine patients reported long-term side. These comprised 
nineteen patients (out of 172 patients, 11.0%) on rhTNFR-Fc treatment and forty (out of 172 
patients, 23.3%) on Infliximab treatment. The percentage suffering from side effect was 
significantly different in these two populations (p-value equals to 0.0013). Overall, thirty-four 
percent of the cohort suffered from late-onset adverse events, affecting 19 patients treated with 
rhTNFR-Fc and 40 patients who were treated with infliximab. Patients experiencing late-onset 
adverse events were free from early-onset complications. Again, patients experiencing late onset 
side effects were slightly but not significantly younger (37 ± 20 vs 42 ± 19, p equals to 0.1461), 
had extended disease duration (p equals to 0.0011) and higher baseline C-reactive protein (p 
equals to 0.0039) and erythrocyte sedimentation rates (p equals to 0.0345). 
 
5.2.4 SNPs in TNFα cannot predict the occurrence of adverse events 
Table 20 details the events count for each genotype in both non-adverse and adverse events 
patients regarding the 4 TNFα SNPs investigated in this cohort. For each genotype, these four 
SNPs were compared between non-adverse and adverse cases. All genotype distributions were in 
Hardy-Weinberg equilibrium. Frequency of A/G and G/G genotype at TNFα -308 polymorphism 
is not significantly different between two groups (p = 0.3 and p = 0.839respectively). Similarly, 
adverse events incidence is not associated with these genotypes at TNFα-238 rs361525. At 
TNFα-1031 and TNFα-857 loci, three polymorphism genotypes, namely C/C, T/T, and C/T, were 
not significantly related to the occurrence of adverse events following anti-TNF therapy (p = 
0.207 and 0.116 respectively). In summary, the SNPs investigated in this study cannot 
effectively predict the occurrence of adverse effects.   
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5.3 Discussion 
Given the clinical efficacy, anti-TNFα therapy is chosen as an effective treatment for a broad 
spectrum of rheumatic diseases in China (Callhoff et al., 2015; Tong et al., 2013). However, the 
adverse events have been constitutively reported in clinical applications, firmly against the 
original drug-safety profiles (Nagy et al., 2011). In China, a lower dosage of TNFα blocker was 
prescribed to patients that reported in the literature. This might explain the milder adverse effect 
and better tolerability. As this therapy is becoming increasingly utilized clinically, both patients 
and clinicians are eager to understand in great details of the adverse effect and to make better and 
safer medical care to a broader patient population. To achieve so, we ought to first profile the 
adverse effects in Chinese Han populations to record the details of information related to clinical 
features, treatment, and responses.  
Our study undertook this aim and provided the first report on adverse events in Chinese Han 
patients, separated by their onset stage. The AS patients were under long-term monotherapy of 
rhTNFR-Fc and Infliximab. Regarding short-term treatment, our analysis showed that about 10% 
adverse effect is moderate, in agreement with literature report in which 13.2% were reported 
with infliximab infusion (De Moraes et al., 2010; Fouache et al., 2009; Gerloni, Pontikaki, 
Gattinara, & Fantini, 2008). There were less than 1% of severe adverse events occurred in our 
study. These severe events, however, are generally fatal, suggesting monitoring treatment and 
making an appropriate decision is critical to patients’ safety. At an early stage, patients may 
exhibit high tolerance, and they should be aware of adverse effects emerging later or long-term 
wise. Long-term treatment usually leads to infectious disease, a consistent observation with 
previous reports (Dixon et al., 2006; Suwannalai, Auethavekiat, Udomsubpayakul, & 
Janvitayanujit, 2009). This is because the function of TNF is to activate macrophage and 
dendritic cells, leading to an induction of innate immunity or regulating acute-phase response 
(Waters et al., 2013). However, TNFi blocks these roles played by TNF, resulting in increased 
risks of infections (Michaud et al., 2014). 
To reduce the chance of side effects, we need to be able to screen patients at high risk. Our result 
suggests that shorter disease duration is a risk factor for both short- and long-term side effects. 
Additionally, if the adverse effects show within two hours of therapy initiation, these patients 
have a higher chance to suffer from peripheral joint symptoms. Lastly, the incidence of adverse 
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effect could be predicted by serum CRP and ESR. These biomarkers are elevated in patients 
comparing to healthy people. However, they are lower in adverse than non-adverse events 
patients for short-term treatment, and higher than non-adverse events patients for long-term 
treatment.  This phenomenon might be attributed to that CRP is able to react with nuclear antigen 
and to indorse the phagocytosis (Peisajovich, Marnell, Mold, & Du Clos, 2008).  
Also, because SNPs in TNFα have been widely investigated in the field of immune disease, and 
specifically AS, we set out to examine whether these SNPs can be used to determine the adverse 
effects. Unfortunately, with limited AS cases recruited to our study, we could not prove their 
efficiencies in predicting the incidences of side effects following therapy administration. This 
result indicated that several approaches could be taken to explore side-effects-related genotypes 
in future study: 1) enlarge the clinical trial by recruiting more patients, which may improve the 
statistical power; 2) investigate other polymorphisms on TNFα and other infection-associated 
genes; 3) stratify patients by their clinical characteristics and refine the association analysis.  
We appreciate the fact that this study comprises a broad range of patients with varied age and 
disease duration, alluding to a heterogeneous population and thus an averaged result. More 
critically, a significant loss of follow-up rendered the study with limited information and 
statistical power, mainly as a result of the unsolvable financial burden of these expensive drugs. 
Last but not least, we were not able to evaluate the correlation between disease activity and the 
incidence of adverse effects since the BASDAI was not used when the study was designed 
initially.  
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6. RESEARCH SUMMARY AND FUTURE DIRECTIONS 
The current research thesis, for the first time, comprehended the genomic and pharmaceutical 
investigations in Chinese Han AS patients. It also for the first time revealed the adverse 
outcomes in the real world by following up the biological agent therapy, providing the first-hand 
predictive data and relevant experiences regarding TNFα blocker usage. Nowadays, there are not 
too many therapeutic options for AS patients clinically. The evidence-based clinical evaluations 
are only available for NSAIDs and TNFα blocker. Unfortunately, as the first-line treatment for 
AS patients, NSAIDs are not efficiently benefiting the entire population (Taurog et al., 2016). As 
a consequence, biological agents, namely TNF blocker, inevitably become a preferred choice for 
Chinese AS population. However, it is well known that the cost of TNF blocker is relatively 
high, bringing economic burden globally, especially in developing countries like China.  
Our cohort study recruited the greatest number of Chinese AS patients who were treated with 
TNF blocker. The advantage comes from several reasons. First, the hospital where samples were 
collected from locates in Shanghai, a metropolitan city which has the largest population in China. 
Second, the medical insurance system of Shanghai covers the cost of rhTNFR-Fc, making it 
possible for us to continue following these patients. However, several hurdles remain to be 
resolved. Specifically, when patients need to make a choice between different medical 
treatments, clinicians and patients both face the uncertainty of treatment effects, the high cost of 
medication, and unknown side effects. Due to these limitations, we took a different perspective 
to investigate whether any genetic variant is related to AS and whether any genetic information 
can predict the treatment efficacy and levels of adverse effects. Our association study revealed 
that AS patients carrying genotypes of TNFα -857 C/C and/or -1031 T/T exhibited a better 
response to TNF blockers. Meta-analysis suggested that TNFα -308 G/G and -857 C/C predicted 
better response toward the TNFi therapy. We also profiled multiple major adverse events for AS 
patients treated with TNFi monotherapy, namely infliximab and rhTNFR-Fc, with the latter 
being a domestic biosimilar of etanercept. Our results suggested short-term side effects occurred 
at a frequency of ~20% whereas long-term side effects occurred in 59% of patients. Importantly, 
more adverse events were found in the group treated with infliximab than those treated with 
rhTNFR-Fc.  
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Moreover, CRP, ESR and disease duration have a significant relationship to both short- and 
long-term side effects. However, when we tried to establish a link between AS-associated 
genetic variants in TNFα with the frequencies of adverse events, we could not find a significant 
relationship in-between. Recruiting more patients and a greater number of genetic loci for 
analysis might shed light on this perspective. In light of such discoveries, clinicians will have 
data specific to Chinese Han AS patients in the real world. When it is time to decide between 
TNF blocker and other treatments, the patients can first go through a test designed for TNF 
SNPs. If mutations occurred at such locus (loci), clinicians could make an evidence-based 
decision that which treatment strategy is suitable for the patient.  
There are several limitations that need to be addressed regarding this study, which certainly 
should be taken into considerations when one needs to interpret these results for designing future 
studies. First, our investigation is based on a single-centered study. A multi-centered research is 
expected to be conducted in the future to have more and diversified patients involved. Secondly, 
only two TNF inhibitors were included in our study, namely Infliximab and rhTNFR-Fc, hence 
we are not able to provide a complete profile of adverse events for all commonly used TNFi and 
cannot rule out the possibility that the SNPs investigated in this study could be associated with 
the incidence of side effects. Thirdly, many other genetic variants, such as those on TNF receptor 
and IL-10, were not investigated in our study. They might convey significant associations to AS 
development, responses and adverse events of TNFi.  
As a summary, our study presented several novel findings in the field: 1) For the first time, it was 
revealed and validated AS-related SNP positions in a Chinese Han population using a large 
cohort study; 2) these newly revealed SNP positions exhibited strong predictive values for the 
efficiency of AS treatment, therefore is expected to reduce the medical cost for patients 
significantly; 3) side effects of current AS treatment were investigated, which will profoundly 
improve the  effectiveness in surveilling incidences of tuberculosis and infectious diseases; 4) 
pharmacogenomic analysis showed little relationship between TNFα variants and adverse events, 
suggesting a bridge between genetics and side effects of TNFi are not yet able to be established 
by these known and well-defined SNPs; other polymorphisms at different loci and genes might 
serve as better predictors. In future studies, to identify more AS-associated SNPs with prognostic 
and diagnostic values in the Chinese Han population, it is imperative to enlarge the cohort size in 
44 
 
order to acquire a shred of stronger and substantial evidence. Meanwhile, it is currently less clear 
how SNPs are associated with gene transcription regulation and protein function. It is hence 
worthy of more devotion to investigating the impact of SNPs and the exact mechanisms by 
which SNPs affect genes, proteins, and ultimately disease.     
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Table 1. SNPs in TNFα and associated disease. 
SNP  Disease P values and OR Populations References 
rs1799724 
 
MS p<0.001 Turkish 
(Akcali et al., 
2010) 
rs1800629 
 
Asthma 
OR = 1.37, 
p = 0.04 
China 
(Gao, Shan, Sun, 
Thompson, & Gao, 
2006) 
rs1799964 
 
Bowel disease p= 0.00004 UK white Caucasoid 
(Ahamad et al., 
2003) 
rs1800629 
 
Irritation  USA 
(Davis, Visscher, 
Wickett, & Hoath, 
2010) 
rs1800629, 
rs361525 
 Ischemic strokes and 
silent brain 
infarctions 
p<0.05 Koreans (Kim et al., 2010) 
rs1800629 
 
SAD  
OR = 2.635, 
p < 0.01 
Southern China 
(L. Yang, Lu, 
Jiang, Liu, & 
Peng, 2009) 
rs1800629 
 
Worsened labile 
anger 
p<0.05 USA 
(Lotrich, Ferrell, 
Rabinovitz, & 
Pollock, 2010) 
rs361525 
 
New ICH p= 0.003 Northern California 
(Achrol et al., 
2006) 
rs1799964 
 
Endometriosis.  
p = 0.04; 
OR = 1.75, 
1.019–3.01 
Japanese 
(Asghar et al., 
2004) 
rs2229094 of 
LTA 
 Proliferative 
Vitreoretinopathy 
p= 0.0283 Spain (Rojas et al., 2010) 
rs361525 
 Invasive breast 
cancer risk  
OR 1.00 (0.95–
1.06) 
Europe, USA and Australia 
(Gaudet et al., 
2009) 
rs1799724, 
rs1800610 
 
Prostate cancer risk Significant Nutrition Cohort 
(Danforth et al., 
2008) 
rs1800630, 
rs361525 
 
Lung cancer  p= 0.0001 Taiwan (Shih et al., 2006) 
rs1800629 
 
RCC  Significant Turkey 
(Basturk et al., 
2005) 
rs1800629 
 
HCC 
p<0.001, odds 
ratio 
[OR] = 4.75 
Turkish 
(Akkiz et al., 
2009) 
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rs1800629, 
rs1143627, 
rs1800896, 
rs361525 
 
HCC OR = 1.74 
20 studies Caucasian and 
Asian 
(Y. Yang, Luo, 
Feng, & Bi, 2011) 
rs1800629 
 
rAOM p<0.02 USA 
(McCormick et al., 
2011) 
rs1800750, 
rs361525 
 
rAOM 
Crude OR: 3.10; 
p = 0.05; 
adjusted OR: 
3.06; p = 0.07 
Netherlands 
(Emonts et al., 
2007) 
rs361525 
 
Secondary dengue 
hemorrhagic fever 
p= 0.0009 Thais 
(Vejbaesya, 
Chierakul, 
Luangtrakool, & 
Sermduangprateep, 
2007) 
rs1799964, 
rs1799724, 
rs1800750, 
rs1800629 and 
rs361525 
 
Malaria  
rs1799964 
p = 0.0178, 
rs1800630, 
p = 0.0481 
Indian (Sinha et al., 2008) 
rs1800629 
 
MCL p<0.05 Venezuelan 
(Cabrera et al., 
1995) 
rs1800629, 
rs361525 
 
OLP OR = 10.93 Thais 
(Kimkong, 
Hirankarn, 
Nakkuntod, & 
Kitkumthorn, 
2011) 
Unpublished data. 
MS, multiple sclerosis; SAD, sporadic Alzheimer’s disease; ICH, intracranial haemorrhage; LTA, lymphotoxin 
alpha; RCC, renal cell carcinoma; HCC, hepatic cell carcinoma; rAOM, recurrent acute otitis media; MCL, 
mucocutaneous leishmaniasis; OLP, oral lichen planus; OR, odds ratio.  
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Table 2. SNPs under investigation in this study. 
MHC genes   Non-MHC genes 
HLA-B27tagged rs4349859 ERAP1 rs27044 
TNFα-238 rs361525   rs30187 
TNFα-308 rs1800629   rs17482078 
TNFα-857  rs1799724   rs10050860 
TNFα-1031  rs1799964 ERAP2 rs2549782 
   EXOC3L rs868213 
   FOXP3  rs2232367 
     rs28935477 
   IL-1 rs1143627 
   IL-10-819 rs1800871 
   IL-10-1087 rs1800896 
   IL-23R rs10889677 
     rs11465804 
     rs1495965 
     rs1343151 
     rs1004819 
   LNPEP rs2303138 
   MAP3K1 rs96844 
   MAP3K14 rs4792847 
   TNFRSF1A rs4149577 
   TNFRSF11B rs2073618 
     rs4355801 
      rs3102735 
Unpublished data. 
 
  
48 
 
Table 3. Baseline demographics for identifying AS-related SNPs (Section 2). 
 Ankylosing spondylitis patients Healthy controls 
Total number 149 106 
Gender 86 male 
63 female 
62 male 
44 female 
Age (years) 35.8±7.8 37.4±8.2 
Unpublished data. 
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Table 4. SNPs significantly associated with AS. 
Gene SNP Genotype Patient Control p value 
TNFα-857 rs1799724 CC 64 (43.0%) 73 (68.9%)  
  TT 16 (10.7%) 5 (4.7%)  
  CT 69 (46.3%) 28 (26.4%) 0.0002 
  T 101 (33.9%) 38 (17.9%)  
  C 197 (66.1%) 174 (82.1%) <0.0001 
HLA-B27tagged rs4349859 AA 5 (3.4%) 0  
  AG 26 (17.4%) 4 (3.8%)  
  GG 118 (79.2%) 102 (96.2%) 0.0004 
  A 36 (12.1%) 4 (1.9%)  
  G 262 (87.9%) 208 (98.1%) <0.0001 
TNFα-308 rs1800629 AG 8 (5.4%) 13 (12.3%)  
  GG 141 (94.6%) 93 (87.7%) 0.04838 
  A 8 (2.7%) 13 (6.1%)  
  G 290 (97.3%) 199 (93.9%) 0.0535 
TNFRSF1A rs4149577 CC 69 (46.3%) 32 (30.2%)  
  TT 23 (15.4%) 13 (12.3%)  
  CT 57 (38.3%) 61 (57.5%) 0.008710 
  T 103 (34.6%) 87 (41.0%)  
  C 195 (65.4%) 125 (59.0%) 0.136139 
IL-23R rs1004819 CC 32 (21.5%) 29 (27.4)  
  TT 55 (36.9%) 21 (19.8%)  
  CT 62 (41.6%) 56 (52.8%) 0.01317 
  T 172 (57.7%) 98 (46.2%)  
  C 126 (42.3%) 114 (53.8%) 0.01039 
Unpublished data. 
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Table 5. SNPs not significantly associated with AS. 
Gene SNP Genotype Patient Control p 
TNFα-238 rs361525 AG 9 (6.0%) 7 (6.7%)  
  GG 140 (94.0%) 98 (93.3%) 0.8396 
TNFα-1031 rs1799964 CC 2 (1.3%) 6 (5.7%)  
  TT 110 (73.8%) 68 (64.2%)  
  CT 37 (24.9%) 32 (30.1%) 0.0755 
FOXP3 rs2232367 CC 149 (100%) 106 (100%)  
FOXP3 rs28935477 CC 149 (100%) 106 (100%)  
IL-1 rs1143627 CC 43 (28.9%) 23 (21.7%)  
  TT 32 (21.5%) 17 (16.0%)  
  CT 74 (49.6%) 66 (62.3%) 0.1373 
IL-10-1087 rs1800896 AG 15 (10.1%) 15 (14.2%)  
  AA 132 (88.6%) 89 (84.0%)  
  GG 2 (1.3%) 2 (1.8%) 0.5632 
IL-10-819 rs1800871 CC 15 (10.1%) 13 (12.3%)  
  TT 65 (43.6%) 44 (41.5%)  
  CT 69 (46.3%) 49 (46.2%) 0.8449 
IL-23R rs10889677 AC 60 (40.3%) 41 (38.7%)  
  CC 12 (8.0%) 14 (13.2%)  
  AA 77 (51.7%) 51 (48.1%) 0.4046 
 rs11465804 TT 149 (100%) 106 (100%)  
 rs1495965 AA 31 (20.8%) 24 (23.5%)  
  AG 68 (45.6%) 58 (56.9%)  
  GG 50 (33.6%) 24 (19.6%) 0.1594 
 rs1343151 CC 140 (94.0%) 101 (95.3%)  
  CT 9 (6.0%) 5 (4.7%) 0.6475 
ERAP1 rs27044 CC 37 (24.8%) 30 (28.3%)  
  GG 41 (27.5%) 21 (19.8%)  
  CG 71 (47.7%) 55 (51.9%) 0.3640 
 rs30187 CC 34 (0.228) 23 (21.7%)  
  TT 46 (30.9%) 27 (25.5%)  
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  CT 69 (46.3%) 56 (52.8%) 0.5479 
 rs17482078 CC 132 (88.6%) 98 (92.5%)  
  CT 17 (11.4%) 8 (7.5%) 0.3067 
 rs10050860 CC 131 (87.9%) 98 (92.5%)  
  CT 18 (12.1%) 8 (7.5%) 0.2384 
ERAP2 rs2549782 TT 46 (30.9%) 29 (27.4%)  
  GG 25 (16.8%) 24 (22.6%)  
  GT 78 (52.3%) 53 (50.0%) 0.4881 
TNFRSF11B rs2073618 CC 11 (7.4%) 3 (2.8%)  
  CG 62 (41.6%) 48 (45.3%)  
  GG 76 (51.0%) 55 (51.9%) 0.2807 
 rs4355801 AG 62 (41.6%) 42 (39.6%)  
  AA 74 (49.7%) 58 (54.7%)  
  GG 13 (8.7%) 6 (5.7%) 0.5638 
 rs3102735 CC 3 (2.0%) 0  
  TT 108 (72.5%) 66 (62.3%)  
  CT 38 (25.5%) 40 (37.7%) 0.0471 
MAP3K1 rs96844 CC 93 (62.4%) 54 (50.9%)  
  TT 8 (5.4%) 10 (9.4%)  
  CT 48 (32.2%) 42 (39.7%) 0.1476 
MAP3K14 rs4792847 AG 27 (18.1%) 24 (22.6%)  
  AA 118 (79.2%) 80 (75.5%)  
  GG 4 (2.7%) 2 (1.9%) 0.6341 
LNPEP  rs2303138 AA 30 (20.1%) 17 (16.1%)  
  AG 80 (53.7%) 61 (57.5%)  
  GG 39 (26.2%) 28 (26.4%) 0.6936 
EXOC3L  rs868213 TT 145 (97.3%) 104 (98.1%)  
  CT 4 (2.7%) 2 (1.9%) 0.6787 
Unpublished data. 
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Table 6. Currently known AS-associated SNPs in Chinese Han and other populations. 
Gene SNP Population Citation 
STAT4 rs7574865 Chinese Han (Liu, Zhang, & Dong, 2014) 
FCGR2B rs10917661 Chinese Han (Duan et al., 2012) 
FCRL4b rs2777963 Chinese Han (Zeng et al., 2012) 
IL-12B rs6871626 Chinese Han (Zhang et al., 2015) 
IL-1R2 rs2302589 Chinese Han (Xia et al., 2015) 
RUNX3 rs11249215 Chinese Han (Liu et al., 2015) 
PPARGC1B rs7379457 Chinese Han (Liu et al., 2015) 
 rs32579  (Liu et al., 2015) 
PTPN22 rs1217414 Chinese Han (Tang, Wang, & Chen, 2014) 
ETS4 rs112833 Chinese Han (Shan et al., 2014) 
IL-23R rs17375018 
Chinese Han (Dong, Li, Zhang, Tan, & 
Jiang, 2013) 
ERAP1 rs27434 
Chinese Han (Australo-Anglo-American 
Spondyloarthritis et al., 2010) 
FCRL4 rs2777963 Chinese Han (Zeng et al., 2012) 
2p15 rs10865331 Chinese Han (Zhang et al., 2015) 
5q14.3 rs4552569 Chinese Han (Lin et al., 2011) 
5q14.3 rs17095830 Chinese Han (Wei et al., 2013) 
12q12 (ANO6) rs17095830 Chinese Han (Lin et al., 2011) 
 rs4552569  (Wei et al., 2013) 
 rs1265112  (Lin et al., 2011) 
 rs2516509  (Lin et al., 2011) 
 rs3915917  (Lin et al., 2011) 
 rs2596501  (Lin et al., 2011) 
 rs13202464  (Lin et al., 2011) 
TNFRSF1A rs11616188 Chinese Han (Davidson et al., 2011) 
6q21 rs13210693 Chinese Han (Lin et al., 2011) 
HAPLN1-EDIL3 rs4552569 Chinese Han (Lin et al., 2011) 
2p15 rs10865331 Taiwanese (Wen et al., 2014) 
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ORAI1 rs12313273 Taiwanese (Wei et al., 2011) 
 rs7135617 Taiwanese (Wei et al., 2011) 
STIM1 rs3750996 Taiwanese (Wei et al., 2012) 
IL12B rs3212227 Taiwanese (Wong et al., 2012) 
 rs6556416 European (Evans et al., 2011) 
ETS1 rs1128334 Ningxia (Shan et al., 2014) 
IL-23R 
rs11209026 European 
(Australo-Anglo-American 
Spondyloarthritis et al., 2010) 
 
rs2310173 European 
(Australo-Anglo-American 
Spondyloarthritis et al., 2010) 
 rs11209026 European (Burton et al., 2007) 
2p15 
rs10865331 European 
(Australo-Anglo-American 
Spondyloarthritis et al., 2010) 
21q22 
rs2242944 European 
(Australo-Anglo-American 
Spondyloarthritis et al., 2010) 
 rs27037 European (Burton et al., 2007) 
 rs27434 European (Burton et al., 2007) 
ERAP1 rs30187 European (Evans et al., 2011) 
 rs27037 Taiwanese (Wang et al., 2012) 
RUNX3 rs11249215 European (Evans et al., 2011) 
ANTXR2 
rs4333130 European 
(Australo-Anglo-American 
Spondyloarthritis et al., 2010) 
 rs4389526 European (Evans et al., 2011) 
TNFRSF1A rs11616188 European (Evans et al., 2011) 
PTGER4 rs10440635 European (Evans et al., 2011) 
TBKBP1 rs10781500 European (Evans et al., 2011) 
CARD9 rs10781500 European (Evans et al., 2011) 
Unpublished data. 
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Table 7. TNFα genes associated with AS in Chinese Han population. 
Gene rs number Genotype and allele Case n(%) Control n(%) χ2 p-value 
TNFα-308 rs1800629 A/G 3(2.8) 13(12.3) 6.7602 0.0093 
  
G/G 103(97.2) 93(87.7) 
  
  
A 3(1.4) 13(6.1) 6.4951 0.0108 
  
G 209(98.6) 199(93.9) 
  
TNFα-238 rs361525 A/G 7(6.6) 8(7.5) 0.0717 0.7888 
  
G/G 99(93.4) 98(92.5) 
  
  
A 7(3.3) 8(3.8) 0.0691 0.7926 
  
G 205(96.7) 204(96.2) 
  
TNFα-1031 rs1799964 C/C 12(11.3) 6(5.7) 2.2118 0.3309 
  
T/T 61(57.5) 66(62.3) 
  
  
C/T 33(31.2) 34(32) 
  
  
T 94(62.3) 100(56.2) 1.2448 0.2645 
  
C 57(37.7) 78(43.8) 
  
TNFα-857 rs1799724 C/C 39(36.8) 72(67.9) 23.074 0.00001 
  
T/T 20(18.9) 5(4.7) 
  
  
C/T 47(44.3) 29(27.4) 
  
  
T 87(41) 38(18.1) 26.6368 2.455×10^-7 
    C 125(59) 172(81.9)     
The cohort was comprised of 106 ankylosing spondylitis patients (cases) and 106 healthy patients (controls). p-
values were determined by the χ2 test.Cited from (Tong et al., 2012). 
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Table 8. TNFα gene polymorphism associated with nonresponders and responders. 
Gene number Genotype  Nonresponders Responders χ2 p-value 
TNFα-308 rs1800629 A/G 0(0.0) 3(3.3) 0.272 0.602 
  G/G 8(100) 88(96.7)   
TNFα-238 rs361525 A/G 1(12.5) 5(5.5) 0.634 0.4259 
  G/G 7(87.5) 86(94.5)   
TNFα-1031 rs1799964 C/C 3(37.5) 9(9.9) 5.408 0.06694 
  T/T 3(37.5 57(62.6)   
  T/C 2(30) 25(27.5)   
TNFα-857 rs1799724 C/C 1(12.5) 35(38.5) 3.189 0.203 
  T/T 3(37.5) 15(16.5)   
    C/T 4(50) 41(45)     
The cohort comprised of 99 ankylosing spondylitis patients. Nonresponders were patients who did not fulfill the 
Assessment of SpondyloArthritis International Society (ASAS) improvement criteria 20, 40, 50 and 70 following 
anti-TNF therapy; responders were patients who fulfilled any one of the ASAS 20, 40, 50 and 70 criteria following 
anti-TNF therapy. p-values were determined by the χ2 test. Cited from (Tong et al., 2012). 
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Table 9. Primer sequences for genotyping of TNFα polymorphisms. 
Amplification Target Primer Sequence 
TNFα -857 rs1799724  F-ACGTTGGATGGAGGCTCTTTCACTCCCTG 
 
R-ACGTTGGATGATGGGTAGGAGAATGTCCAG 
TNFα -1031 rs1799964 F-ACGTTGGATGCCCTCCAGACCCTGACTTT 
 
R-ACGTTGGATGGGATATGTGATGGACTCACC 
TNFα -308 rs1800629  F-ACGTTGGATGGATTTGTGTGTAGGACCCTG 
 
R-ACGTTGGATGGGTCCCCAAAAGAAATGGAG 
TNFα -238 rs361525  F-ACGTTGGATGATCAAGGATACCCCTCACAC 
  R-ACGTTGGATGCACACAAATCAGTCAGTGGC 
Cited from (Tong et al., 2012). 
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Table 10. Clinical characteristics of patients with TNFα -857 before treating with TNFα 
blocker and response assessment after anti-TNFα therapy. 
  
All patients 
(n=99) 
C/C genotype 
(n=36) 
T/C genotype 
(n=45) 
T/T genotype 
(n=18) 
Age (years, mean±SD) 41.63±15.82 41.00±14.85 42.98±15.52 39.07±18.27 
Men (%) 77.78 75 75.56 92.86 
Duration (years, mean±SD) 9.45±9.00 10.69±10.86 8.99±7.67 7.36±5.99 
Clinical features     
Axis onset† (%) 54.55 62.5 48.89 50 
Biologic assessment     
HLA-B27 (%) 91.92 90 91.11 100 
Serum CRP (mg/dl, mean±SD) 35.22±18.82 34.68±12.59 35.96±23.14 34.49±18.09 
ESR (mg/dl, mean±SD) 36.42±17.95 37.45±16.21 36.89±18.46 32±20.27 
Drug treatment     
Infliximab, n (%) 28(28.28) 7(19.44) 15(33.33) 6(33.33) 
rhTNFR–Fc, n (%) 71(71.72) 29(80.56) 30(66.67) 12(66.67) 
BASDAI scores     
Week0 (mean±SD) 5.92±1.87 6.18±2.02 5.79±1.83 5.64±1.46 
Week12 (mean±SD) 2.93±1.39 2.86±1.22 2.96±1.56 3.03±1.24 
ASAS     
Nonresponder, n (%) 8(8.08) 1(2.78) 4(8.89) 3(16.67) 
ASAS20, n (%) 20(20.20) 5(13.89) 7(15.56) 8(44.44) 
ASAS40, n (%) 27(27.27) 13(36.11) 12(26.67) 2(11.11) 
ASAS50, n (%) 36(36.36) 12(33.33) 20(44.44) 4(22.22) 
ASAS70, n (%) 8(8.09) 5(13.89) 2(4.44) 1(5.56) 
Total 106 patients were recruited initially. Seven of them were lost during follow-up. †Axis onset means ankylosing 
spondylitis patients that presented with inflammatory back pain and alternating buttock pain symptoms at the 
beginning of the disease. ASAS, Assessment of SpondyloArthritis International Society; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index, ESR, Erythrocyte sedimentation rate; rhTNFR–Fc, Recombinant human TNFα 
receptor II–IgG Fc fusion protein; SD, Standard deviation. Cited from (Tong et al., 2012)
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Table 11. TNFα gene polymorphisms associated with poor and nonresponders versus good responders. 
Gene rs number 
Genotype and 
allele 
Poor and 
nonresponders, n(%) 
Good responders, 
n(%) χ2 
p-
value 
TNFα-308 rs1800629 A/G 1(3.6) 2(2.8) 0.039 0.8436 
  G/G 27(96.4) 69(97.2)   
TNFα-238 rs361525 A/G 3(10.7) 3(4.2) 1.485 0.2229 
  G/G 25(89.3) 68(95.8)   
TNFα-1031 rs1799964 C/C 9(32.1) 3(4.2) 15.645 0.0004 
  T/T 15(53.6) 45(63.4)   
  T/C 4(14.3) 23(32.4)   
  T 34(60.7) 113(79.6) 7.473 0.0063 
  C 22(39.3) 29(20.4)   
TNFα-857 rs1799724 C/C 6(21.4) 30(42.3) 12.285 0.0021 
  T/T 11(39.3) 7(9.9)   
  C/T 11(39.3) 34(47.8)   
  T 33(58.9) 48(33.8) 10.488 0.0012 
    C 23(41.1) 94(66.2)     
The cohort comprised of 99 ankylosing spondylitis patients. Nonresponders were patients who did not fulfill the Assessment of SpondyloArthritis International 
Society (ASAS) 20 improvement criteria; good responders met the ASAS 40, 50 and 70 criteria. p-values were determined by χ2 test. Cited from (Tong et al., 
2012). 
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Table 12. Summary of studies included in the meta-analysis. 
year country disease 
patient 
number 
TNF 
inhibitor 
Follow-
up period 
Response 
criteria 
TNFa-
308 
Respon
der (n) 
Nonresp
onder 
(n) 
TNF-
a-857 
Respon
der (n) 
Nonres
ponder 
(n) Ref 
2000 Belgium CD 77 Infliximab  - CDAI G/G 47 12  -  -  - 
(Vermeire et 
al., 2000) 
       G/A 7 9  -  -  -  
       A/A 1 1  -  -  -  
2002 Belgium CD 214 Infliximab 18 weeks CDAI G/G 116 35  -  -  - 
(Louis et al., 
2002) 
       G/A 39 18  -  -  -  
       A/A 3 3  -  -  -  
2007 Switzerland AS 22 
Infliximab
, 
adalimum
ab and 
etanercept 24 weeks BASDAI G/G 16 0  -  -  - 
(Seitz et al., 
2007) 
       G/A 4 2  -  -  -  
       A/A 0 0  -  -  -  
  PsA 10 
Infliximab
, 
adalimum
ab and 
etanercept 24 weeks DAS28 G/G 10 0  -  -  -  
       G/A 0 0  -  -  -  
       A/A 0 0  -  -  -  
2009 Denmarkd CD 16 Infliximab 30 days 
Clincal 
Ourcome G 26 1 C 30 2 
(Seitz et al., 
2007) 
       A 4 1 T 0 0  
 Denmarkd CD 15 Infliximab 6 years 
Clincal 
Ourcome G 23 2 C 28 2  
       A 5 0 T 0 0  
 Czech CD 36 Infliximab 30 days 
Clincal 
Ourcome G 61 1 C 62 2  
       A 9 1 T 8 0  
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 Czech CD 34 Infliximab 4 years 
Clincal 
Ourcome G 59 0 C 8 0  
       A 9 0 T 60 0  
2012 China AS 99 
Infliximab 
and 
rhTNFR-
Fc 12 weeks BSDAI G/G 88 8 C/C 35 1 
(Tong et al., 
2012) 
       G/A 3 0 C/T 41 4  
       A/A 0 0 T/T 15 3  
2012 Greece PS 80 
Infliximab
, 
adalimum
ab and 
etanercept 6 months PASI  -  -  - C/C 41 6 
(Vasilopoulos 
et al., 2012) 
        -  -  - C/T 20 9  
               -  -  - T/T 2 2   
rhTNFR-Fc (Product name: YiSaiPu), recombinant human TNF‑α receptor II–IgG Fc fusion protein, is a TNF blocker manufactured in China and the effect is 
similar to that of etanercept (Huang et al., 2011). –, Unavailable data; AS, Ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Activity Index; CD, 
Crohn’s disease; CDAI, Crohn’s Disease Activity Index; DAS28, Disease Activity Score 28; PASI, Psoriasis Area and Severity Index; PS, Psoriasis; PsA, 
Psoriatic arthritis.Cited from (Tong et al., 2013).Nonresponders were patients who did not fulfill the Assessment of SpondyloArthritis International Society 
(ASAS) improvement criteria 20, 40, 50 and 70 following anti-TNF therapy; responders were patients who fulfilled any one of the ASAS 20, 40, 50 and 70 
criteria following anti-TNF therapy.
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Table 13.Association of -308 A/G polymorphism at TNFα promoter and response to TNF 
blockers. 
Polymorphism Pooled  Test of heterogeneity Effects  Test of association 
  studies Q p-value I2(%) model OR 95% CI Z p-value 
G versus A 
(Duricova et 
al., 2009; 
Louis et al., 
2002; Seitz 
et al., 2007) 4.48 0.48 0 Fixed 2.14 
1.38–
3.33 3.38 0.0007 
GG versus GA+AA 
(Louis et al., 
2002; Seitz 
et al., 2007; 
Tong et al., 
2012) 4.41 0.22 32 Fixed 2.31 
1.36–
3.91 3.11 0.002 
GG+GA versus AA 
(Louis et al., 
2002; Seitz 
et al., 2007; 
Tong et al., 
2012) 0.01 0.94 0 Fixed 1.44 
0.69–
11.60 1.44 0.15 
Publication bias was not detected owing to not enough data included to draw a funnel plot. OR: Odds ratio. I2 was 
used to quantify the effect of heterogeneity. I2 ranges between 0 and100% and this represents the proportion of the 
between-study variability that can be attributed to heterogeneity rather than chance. I2 values of 25, 50 and 75% 
were assigned as low, moderate and high estimates, respectively; CI, confidence interval. Cited from (Tong et al., 
2013). 
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Table 14. Association of -857 C/T polymorphism at TNFα promoter and response to TNF 
blockers. 
Polymorphism Pooled  Test of heterogeneity Effects  Test of association 
  studies Q p-value I2(%) model OR 95% CI Z p-value 
C versus T 
(Duricova et 
al., 2009; 
Tong et al., 
2012) 2.61 0.27 23 Fixed 2.17 1.17–4.03 2.47 0.01 
CC versus 
CT+TT 
(Tong et al., 
2012; 
Vasilopoulos 
et al., 2012) 0.04 0.84 0 Fixed 3.66 1.35–9.92 2.55 0.01 
CC+CT  
versus TT 
(Tong et al., 
2012; 
Vasilopoulos 
et al., 2012) 0.05 0.82 0 Fixed 3.38 1.00–11.48 1.95 0.05 
Publication bias was not detected owing to not enough data included to draw a funnel plot. I2-values of 25, 50 and 
75% were assigned as low, moderate and high estimates, respectively; CI, confidence interval. CI, confidence 
interval. Cited from (Tong et al., 2013). 
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Table 15. Clinical features of patients with TNFα -1031 before treating with TNFα blockers 
and response assessment after anti-TNFα therapy. 
  C/C genotype (n=12) T/C genotype (n=27) T/T genotype (n=60) 
Age (years,mean±SD) 43.58±15.78 43.07±13.25 40.37±16.50 
Men (%) 83.33 81.48 76.67 
Duration (years,mean±SD) 10.00±7.98 9.13±8.27 9.55±9.52 
Clinical features    
Axisonset†(%) 66.67 62.96 46.67 
Biologic assessment    
HLA-B27(%) 91.67 96.29 91.67 
Serum CRP (mg/dl,mean±SD) 38.25±17.62 36.33±24.74 34.28±15.51 
ESR (mg/dl,mean±SD) 29.83±19.02 34.56±18.50 38.85±17.16 
Drug treatment    
Infliximab, n (%) 3(25.00) 7(25.93) 18(30.00) 
rhTNFR–Fc, n (%) 9(75.00) 20(74.07) 42(70.00) 
BASDAI scores    
Week0 (mean±SD) 5.55±1.59 6.10±2.49 5.91±1.57 
Week12 (mean±SD) 3.44±1.72 2.79±1.36 2.88±1.30 
ASAS    
Nonresponder,n(%) 3(25.00) 2(7.41) 3(5.00) 
ASAS20, n(%) 6(50.00) 2(7.41) 12(20.00) 
ASAS40, n(%) 2(16.67) 7(25.92) 18(30.00) 
ASAS50, n(%) 1(8.33) 13(48.15) 22(36.67) 
ASAS70, n(%) 0(0.00) 3(11.11) 5(8.33) 
†Axis onset indicates the symptoms presented at the beginning of the disease.ASAS, Assessment of 
SpondyloArthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index;ESR, 
Erythrocyte sedimentation rate; rhTNFR–Fc, Recombinant human TNF‑α receptor II–IgG Fc fusion 
protein;Nonresponders were patients who did not fulfill the Assessment of SpondyloArthritis International Society 
(ASAS) improvement criteria 20, 40, 50 and 70 following anti-TNF therapy; SD, Standard deviation. Cited from 
(Tong et al., 2012).  
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Table 16. Clinical features of patients with short-term adverse events. 
  All patients 
non-adverse event 
patients adverse event patients p value 
Demographics (n=402) (n=321) (n=81)   
Age±SD (years) 39.6±15.8 42.1±19.0 35.9±17.2 0.075 
Male (%) 93.30% 92.20% 97.5% 0.087 
duration±SD (years) 7.6±8.2 10.1±9.8 6.3±7.6 0.001 
Type     
Axial phenotype (%) 69.20% 75.10% 45.7% 1.02E-07 
Biologic evaluation     
HLA-B27, no (%) 95.5% 98.8% 82.7% 1.76E-09 
Serum CRP±SD (mg/dl) 36.4±18.5 41.5±17.4 31.3±22.4 1.11E-05 
ESR±SD (mg/dl) 32.2±15.3 38.0±16.5 29.9±15.3 1.95E-05 
Drug treatment     
Infliximab (%) 47.8%(192) 48.9%(157) 43.2%(35) 0.3852 
rhTNFR-Fc (%) 52.2%(210) 51.1%(164) 56.8%(46)   
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Infliximab is an antibody biologic drug that works 
against tumor necrosis factor alpha (TNF-α); rhTNFR-Fc (Product name: YiSaiPu), recombinant human TNF‑α 
receptor II–IgG Fc fusion protein, is a TNF blocker manufactured in China and the effect is similar to that of 
etanercept (Huang et al., 2011); SD, Standard deviation. Axial phenotype initially mainly affects the spine and 
pelvic joints. Cited from (Tong et al., 2015). 
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Table 17. Long-term adverse events in two TNFi treatments. 
  
Patients with 
adverse events rhRNFR-Fc Infliximab p-value 
Infectious disease (%) (n=59) (n=19) (n=40)  
Pneumonia 13(22%) 5(26.3%) 8(20%) 0.5844 
Urinary tract infection 17(28.80%) 2(10.5%) 15(37.5%) 0.0325 
Otitis media 8(13.6%) 1(5.3%) 7(17.5%) 0.1995 
Tuberculosis 6(10.2%) 4(21.1%) 2(5%) 0.0566 
Abscess 2(3.4%) 0(0%) 2(5%) 0.3213 
Oral candidates 1(1.7%) 0(0%) 1(2.5%) 0.4869 
The other AEs (%)     
Elevation of transaminase 3(5.1%) 2(10.5%) 1(2.5%) 0.1897 
Anemia 2(3.4%) 1(5.3%) 1(2.5%) 0.5836 
Hematuresis 1(1.7%) 0(0%) 1(2.5%) 0.4869 
Constipation 4(6.8%) 4(21.1%) 0(0%) 0.0026 
Weight loss 1(1.7%) 0(0%) 1(2.5%) 0.4869 
Exfoliative dermatitis 1(1.7%) 0(0%) 1(2.5%) 0.4869 
AE, adverse events;rhTNFR-Fc (Product name: YiSaiPu), recombinant human TNF‑α receptor II–IgG Fc fusion 
protein, is a TNF blocker manufactured in China and the effect is similar to that of etanercept (Huang et al., 
2011);Infliximab is an antibody biologic drug that works against tumor necrosis factor alpha (TNF-α).Cited from 
(Tong et al., 2015). 
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Table 18. Short-term adverse events in two TNFi treatments. 
  
Patients with adverse 
events rhRNFR-Fc Infliximab p-value 
Mild (%) (n=81) (n=46) (n=35)   
rash 14(17.3%) 11(23.9%) 3(8.6%) 0.0704 
pruritus 5(6.2%) 2(4.4%) 3(8.6%) 0.4339 
nausea 9(11.1%) 4(8.7%) 5(14.3%） 0.4277 
headache 3(3.7%) 1(2.2%) 2(5.7%) 0.4032 
Moderate (%)     
skin allergies 16(19.8%) 12(26.1%) 4(11.4%) 0.1007 
fever 2(2.5%) 2(4.6%) 0(0%) 0.2116 
palpitations 12(14.8%) 8(17.4%) 4(11.4%) 0.4542 
dyspnea 2(2.5%) 1(2.2%) 1(2.9%) 0.8443 
chest pain 1(1.2%) 0(0%) 1(2.9%) 0.2486 
abdominal pain 4(4.9%) 1(2.2%) 3(8.6%) 0.188 
hypertension 9(11.1%) 2(4.4%) 7(20%) 0.0263 
Severe (%)     
papilledema 2(2.5%) 2(4.4%) 0(0%) 0.2116 
laryngeal edema 1(1.2%) 0(0%) 1(2.9%) 0.2486 
premature ventricular contraction 1(1.2%) 0(0%) 1(2.9%) 0.2486 
Mild adverse outcomes refer to any complications that can be solved in 1 hour (include 14 cases of rushes, 5 cases 
of pruritus, 9 cases of nausea, 3 cases of headache). Total eleven cases were recorded in rhTNFR-Fc group.Moderate 
adverse outcomes refer to complications that could be resolved immediately by medical treatment (include 16 cases 
of akin allergies, 2 cases of fever, 12 cases of palpitations, 2 cases of dyspnea, 1 case of chest pain, 4 cases of 
abdominal pain, 9 cases of hypertension). Severe adverse outcomes refer to fatal events that require inpatient 
hospitalization (include 2 cases of papilledema, 1 case of laryngeal edema, 1 case of premature ventricular 
contraction). rhTNFR-Fc (Product name: YiSaiPu), recombinant human TNF‑α receptor II–IgG Fc fusion protein, is 
a TNF blocker manufactured in China and the effect is similar to that of etanercept (Huang et al., 2011);Infliximab 
is an antibody biologic drug that works against tumor necrosis factor alpha (TNF-α).Cited from (Tong et al., 2015). 
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Table 19. Clinical features of AS patients with long-term adverse events. 
  All patients 
non-adverse event 
patients adverse event patients p value 
Demographics (n=172) (n=113) (n=59)   
Age±SD (years) 40.6±18.5 42.3±19.6 37.7±20.2 0.1461 
Male (%) 98.80% 98.20% 100% 9.39E-17 
duration±SD (years) 9.8±8.5 10.9±9.5 6.3±6.5 0.0011 
Type     
Axial phenotype (%) 98.30% 99.10% 98.30% 0.6381 
Biologic evaluation     
HLA-B27, no (%) 100% 100% 100%  
Serum CRP±SD (mg/dl) 39.6±17.3 35.7±19.6 44.8±18.7 0.0039 
ESR±SD (mg/dl) 38.5±18.7 36.9±18 42.9±16.5 0.0345 
Drug treatment     
Infliximab (%) 50.6%(87) 41.6%(47) 67.8%(40) 0.0013 
rhTNFR-Fc (%) 49.4%(85) 58.4%(66) 32.2%(19)   
CRP: C-reactive protein. ESR: erythrocyte sedimentation rate; Infliximab is an antibody biologic drug that works 
against tumor necrosis factor alpha (TNF-α); rhTNFR-Fc (Product name: YiSaiPu), recombinant human TNF‑α 
receptor II–IgG Fc fusion protein, is a TNF blocker manufactured in China and the effect is similar to that of 
etanercept (Huang et al., 2011); SD, Standard deviation. Axial phenotype initially mainly affects the spine and 
pelvic joints. Cited from (Tong et al., 2015). 
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Table 20. TNFα gene polymorphisms associated patients with long-term non-adverse 
events and adverse events. 
Gene rs Genotype 
Non-adverse events 
patients (n=82) 
Adverse event 
patients (n=39) 
χ2 p-value 
TNFα-308 rs1800629 A/G 3 4 1.074 0.3 
  G/G 79 35   
TNFα-238 rs361525 A/G 4 3 0.041 0.839 
  G/G 78 36   
TNFα-
1031 
rs1799964 C/C 5 5 3.153 0.207 
  T/T 52 27   
  T/C 25 7   
TNFα-857 rs1799724 C/C 39 18 4.315 0.116 
  T/T 8 9   
    C/T 35 12     
Unpublished data. 
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Figure 1. Genomic location of investigated SNPs on TNF gene. 
 
The gene structure of TNFαis shown above. Each solid box indicates an exon, each line in 
between two boxes indicates an intronic region. Promoter (-1.5kb) of TNFα is drawn as dashed 
line, with four investigated SNPs marked at relative position.   
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Figure 2. The networks formed by susceptible genes and protein products in AS. 
Unpublished data. The network view summarizes the network constructed by the transcribed 
protein products of SNP-associated genes. Each node represents a protein. Blue lines connecting 
each node suggests that their relationship is predicted based on experimental evidences. The 
thickness of the lines represents the degree of confidence prediction of the interaction. Medium 
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level confidence (0.400) was used to build the network. ANTXR2:Anthrax toxin receptor 2; 
ERAP1:Endoplasmic reticulum aminopeptidase 1;CARD9:Caspase recruitment domain family, 
member 9; PTPN22:Protein tyrosine phosphatase, non-receptor type 22 (lymphoid); IL-23R: 
Interleukin 23 receptor; TNFRSF1A: Tumor necrosis factor receptor superfamily, member 1A; 
PTGER4:Prostaglandin E receptor 4 (subtype EP4); STAT4:Signal transducer and activator of 
transcription 4; TBKBP1:TBK1 binding protein 1; TNF: Tumor necrosis factor; IL12B: 
Interleukin 12B; PPARGC1B:Peroxisome proliferator-activated receptor gamma, coactivator 1 
beta; ESR1: Estrogen receptor 1; RUNX3:Runt-related transcription factor 3; ORAI1:ORAI 
calcium release-activated calcium modulator 1; STIM1:Stromal interaction molecule 1; 
FCGR2B:Fc fragment of IgG, low affinity IIb, receptor (CD32); HRAS:v-Ha-ras Harvey rat 
sarcoma viral oncogene homolog; ETS1:V-ets erythroblastosis virus E26 oncogene homolog 1 
(avian); FCRL4:Fc receptor-like 4. 
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Figure 3. Study selection for the meta-analysis (Section 4). 
 
A total of six relevant studies met the inclusion criteria for the meta-analysis. The flow chart 
showed the process of the meta-analysis, including the inclusion and exclusion criteria for initial 
study selection, assessment for eligibility, separation based on SNP targets, and finally the 
comparison results.   
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Figure 4. Association of -308 A/G polymorphism at TNFα promoter and response to TNF 
blockers (G allele vs A allele). 
 
Duricova 1 and Duricova 2 refer to the results of patients from two different countries. Seitz 1 
and Seitz 2 refer to the results of two different subsets. Cited from(Tong et al., 2013). 
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Figure 5. Association of -308 A/G polymorphism at TNFα promoter and response to TNF 
blockers (G/G vs [G/A+A/A] genotypes). 
 
Seitz 1 and Seitz 2 refer to the results of two different subsets. Cited from (Tong et al., 2013). 
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Figure 6. Association of -308 A/G polymorphism at TNFα promoter and response to TNF 
blockers ([A/G+G/G] vs A/A genotypes). 
 
Seitz 1 and Seitz 2 refer to the results of two different subsets. Cited from (Tong et al., 2013). 
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Figure 7. Association of -857 C/T polymorphism at TNFα promoter and response to TNF 
blockers (C allele vs T allele). 
 
Duricova 1 and Duricova 2 refer to the results of patients from two different countries. Cited 
from (Tong et al., 2013). 
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Figure 8. Association of -857 C/T polymorphism at TNFα promoter and response to TNF 
blockers (C/C vs [C/T+T/T] genotypes). 
 
Cited from (Tong et al., 2013).  
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Figure 9. Association of -857 C/T polymorphism at TNFα promoter and response to TNF 
blockers ([C/T+C/C] vs T/T genotypes). 
 
Cited from (Tong et al., 2013).  
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